

TO WHOM IT MAY CONCERN

To any governmental departments,
registration and/or trade offices in MOLDOVA

Distribution Authorisation Letter

This letter confirms that **Sanmedico**
Mun. Chisinau
Str. Petricani 88/1 of. 10
Republica MOLDOVA

is the **legal, exclusive and sole** representative of **TECO Medical Instruments Production + Trading GmbH, Dieselstr. 1, 84088 Neufahrn NB, Germany**, for the territory of **MOLDOVA** only for all TECO products listed below. **Sanmedico** may participate in public and private tenders, providing sales to all TECO customers in the territory. We as manufacturer certify that our warranty is duly passed to the purchaser through **Sanmedico** for the price, delivery schedules and the specifications of the published literature, catalogues and fully covering the commodities offered.

Sanmedico will provide the following information to TECO GmbH when so required in relation to its market surveillance activities:

Reporting of incidents to TECO must take place within 3 working days
Serial number of the device, exact location of the device and the user.

Validity: January 1st, 2023 to December 31st, 2024


Termination: Confirmation ends automatically on Dec. 31st of 2024
and must be then renewed.

Products:

- Coatron M1 Semi-automated 1-channel Coagulometer (out of production)
 - Coatron M2 Semi-automated 2-channel Coagulometer (out of production)
 - Coatron X Eco Semi-automated 1-channel Coagulometer
 - Coatron X Pro Semi-automated 2-channel Coagulometer
 - Coatron X Top Semi-automated 4-channel Coagulometer
 - Coatron A4 Fully automated Coagulometer, 4 optic channels
 - Coatron A6 Fully automated Coagulometer, 6 optic channels
 - Coatron A6 plus Fully automated Coagulometer, 6 optic channels
 - Hemostasis Reagents Complete product line
- all instruments with complete accessory, consumables and spare parts

This document is signed in Neufahrn, Germany, on January 18th, 2023

TECO Medical Instruments Production+Trading GmbH


Christian Hoetzl



Certificate of Approval

This is to certify that the Management System of:

TECO Medical Instruments, Production + Trading GmbH

Dieselstr. 1, 84088 Neufahrn, Germany

has been approved by LRQA to the following standards:

ISO 13485:2016

Approval number(s): ISO 13485 – 00038268

The scope of this approval is applicable to:

Design, development, manufacturing, storage and sales of coagulation instruments and in-vitro-diagnostic reagents used in the hemostaseology and coagulation.



Paul Graaf

Area Operations Manager, Europe

Issued by: LRQA Limited



0001





KONFORMITÄTSERKLÄRUNG DECLARATION OF CONFORMITY

Doc#001-01/06-2022

Hersteller / Manufacturer: **TECO Medical Instruments
Production and Trading GmbH**
Adresse / Address: **Dieselstrasse 1, 84088 Neufahrn, Germany**
Marktakteur / Actor ID SRN: **DE-MF-000022642 <https://ec.europa.eu>**

Die hier benannten Produkte der generischen Produktgruppe erfüllen die Anforderungen der aufgeführten Verordnungen, Richtlinien und Normen. Im Falle eigenmächtiger Veränderungen am Produkt oder der nicht bestimmungsgemäßen Verwendung verliert diese Erklärung ihre Gültigkeit.

Diese Konformitätserklärung wird unter der alleinigen Verantwortung des Herstellers ausgestellt.

BASIS UDI-DI 426018278CMX81152

IVD - halb-automatische Blutgerinnungsmessgeräte - Handelsbezeichnung, Typ, Kat.-Nr.
IVD - semi-automated Coagulation Systems - trade name, type, model, Cat.-No.

Coatron X Eco / Coatron X Pro / Coatron X Top

81 101 10

81 101 20

81 101 40

The products of the generic product group named here fulfil the requirements of listed regulations, directives and standards. In the case of unauthorised modifications to the product or use not in accordance with the intended purpose, this declaration becomes invalid.

This declaration of conformity is issued under the sole responsibility of the manufacturer.

Verordnung (EU) 2017/746

für in-vitro Diagnostika-IVDR
und dem harmonisierten Standard am 2022-05-12:
Risikoklassifizierung gemäß Artikel 47–Anhang VIII
Regel 5 b – „Klasse A“

Konformitätsbewertungsverfahren gemäß:
(EU) 2017/746 Artikel 17 (Anhang II+III)

Angewandte Normen zur Sicherstellung der
grundlegenden Anforderungen an Leistung und
Sicherheit:

EN ISO 18113-3:2011
DIN EN 62304:2018
DIN EN 62366-1
DIN EN 62366-1:2017
DIN EN 61326-1:2013
DIN EN 55011:2009 + A1:2010
IEC 61010-1:2010, AMD1:2016
IEC 61010-2-101:2015
IEC 61010-1:2010

Richtlinie 2011/65/EU RoHS III
(incl. (EU) 2015/863) - DIN EN IEC 63000

QM-System gemäß (EU) 2017/746 Art.10(8)
angewandter Standard: EN ISO 13485:2021

Regulation (EU) 2017/746

for In-vitro diagnostic medical devices
and it's harmonized standard at 2022-05-12:
Risk classified according to article 47 annex VIII
Rule 5 b – "Class A"

Conformity assessment procedure in accordance with:
(EU) 2017/746 Article 17 (annex II+III)

Standards applied to ensure the essential requirements
for performance and safety:

EN ISO 18113-3:2011
DIN EN 62304:2018
DIN EN 62366-1
DIN EN 62366-1:2017
DIN EN 61326-1:2013
DIN EN 55011:2009 + A1:2010
IEC 61010-1:2010, AMD1:2016
IEC 61010-2-101:2015
IEC 61010-1:2010

Directive 2011/65/EU RoHS III
(incl. (EU) 2015/863 - DIN EN IEC 63000

QM-Systems in accordance with (EU) 2017/746 art.10(8)
Applied standard procedure: EN ISO 13485:2021

Ort und Datum der Unterzeichnung: Neufahrn, 2022-06-21
Place and date of issue:

Matthias Dieckmann
General Manager



Christian Hötzel
Verantwortliche Person / PRRC



KONFORMITÄTSERKLÄRUNG DECLARATION OF CONFORMITY

Doc#200/08-2022

Hersteller / Manufacturer: **TECO Medical Instruments
Production + Trading GmbH**
 Adresse / Address: **Dieselstrasse 1, 84088 Neufahrn, Germany**
 Marktakteur / Actor ID SRN: **DE-MF-000022642 <https://ec.europa.eu>**

Wir erklären hier für die im Anhang A (Seite 2 – 23 IVD Produkte) spezifizierten Produkte dass sie gemäß der Richtlinie für In-vitro-Diagnostika Medizinprodukte 98/79/EC klassifiziert sind als allgemeine IVD.

Diese Konformitätserklärung wird unter der alleinigen Verantwortung des Herstellers i.V.m. Artikel 110 Abs.3 und Abs.4 der Verordnung (EU) 2017/746 und des § 8 Abs.1 des Medizinprodukte-Durchführungsgesetzes, in der jeweils geltenden Fassung, ausgestellt.

Im Falle eigenmächtiger Veränderungen am Produkt oder der nicht bestimmungsgemäßen Verwendung verliert diese Erklärung ihre Gültigkeit.

We declare herewith for the products specified in Annex A (page 2 - 23 IVD products) that they are classified as general IVD according to the In Vitro Diagnostic Medical Devices Directive 98/79/EC.

This declaration of conformity is issued under the sole responsibility of the manufacturer in according to article 110 para.3 and para.4 of Regulation (EU) 217/746 and section 8 para.1 of the Medical Device Law Implementing Act.

In case of unauthorised modifications to the products or un-intended use, this declaration loses its validity.

Sie entsprechen den anwendbaren Anforderungen der Richtlinie:	They meet applicable requirements of:
Richtlinie 98/79/EG über In-vitro-Diagnostika klassifiziert gemäß Artikel 9 als "alle anderen Produkte"	Directive 98/79/EC on in-vitro-diagnostic medical devices classified according to article 9 as „all other products“
Die Qualitätssicherung entspricht den Anforderungen der Richtlinie 98/79/EG über In-vitro-Diagnostika für diese Art von Produkten.	The Quality Assurance is in accordance with the requirements of Directive 98/79/EC on in-vitro-diagnostic medical devices for those kind of products.
Der implementierte QM-Prozess entspricht der EN ISO 13485:2021	The implemented QM Process complies with EN ISO 13485:2021
Die vorstehende Konformitätserklärung ist gültig für alle Chargen dieser Produkte, die nach dem Datum der Unterzeichnung in Verkehr gebracht wurden.	The above mentioned declaration of conformity is valid for all lots of this product, which are distributed after the date of signature.
Das Konformitätsbewertungsverfahren entspricht Anhang III der Richtlinie 98/79/EG über In-vitro-Diagnostika für diese Art von Produkten.	The conformity assessment procedure complies with Annex III of Directive 98/79/EC on in-vitro-diagnostic medical devices for those kind of products.

Ort und Datum der Unterzeichnung: **Neufahrn, 2022-08-31**
Place and date of issue:



Christian Hötzi
Verantwortliche Person / PRRC

Doc#200/08-2022

KONFORMITÄTSERKLÄRUNG – DECLARATION OF CONFORMITY

Directive 98/79/EC Annex A

Übrige Produkte – Reagenzien für In-vitro-Diagnostika

Other products – Reagents for in vitro diagnostic – general IVD

Pos.	Article No	Tradename	Unit	Generic Device Term	EMDN / GMDN Code EUDAMED DI
1	A0230-040	TEClot PT-S (Quick)	10x4ml PT-S	Prothrombin time (quick test)	W0103020101 / 30539 B-PTS-A0230-040X7
2	A0230-100	TEClot PT-S (Quick)	10x10ml PT-S	Prothrombin time (quick test)	W0103020101 / 30539 B-PTS-A0230-100WY
3	A0260-050	TEClot PT-B (Owren)	5x10ml PT-B	Prothrombin time (quick test)	W0103020199 / 55986 B-PTB-A0260-050G2
4	A0320-050	TEClot APTT-S	10x5ml APTT-S	Activated partial thromboplastin time	W0103020102 / 55982 B-APTT-A0320-050AM
5	A0401-020	TEClot TT	10x2ml TT	Thrombin time / reptilase / batroxbin time	W0103020103 / 55988 B-TT-A0401-0207P
6	A0511-020	TEClot FIB	10x2ml FIB	Fibrinogen assays (factor i)	W0103020201 / 55997 B-FIB-A0511-020N2
7	A0511-050	TEClot FIB	10x5ml FIB	Fibrinogen assays (factor i)	W0103020201 / 55997 B-FIB-A0511-050NB
8	C1010-020	TEChrom AT	6x6ml reagent FXa 3x3 ml substrate	Antithrombin	W0103020602 / 56156 B-AT-C1010-020HL
9	D2010-012	Red D-Dimer	3x4ml latex 3x7ml reaction buffer	D-Dimer	W0103020503 / 47349 B-DD-D2010-0126W
10	D2020-005	Blue D-Dimer LC	1x5ml latex LC 1x7ml reaction buffer	D-Dimer	W0103020503 / 47349 B-DD-D2020-0057E
11	P8001-010	TECaL N	10x1ml	Calibration plasma for haemostasis	W0103020701 / 45786 B-CAL-P8001-005X8
12	P8200-005	TECaL DD	5x1ml	Calibration plasma for haemostasis	W0103020701 / 47348 B-CAL-P8200-005XX
13	P6001-010	TEControl N	10x1ml	Control plasma for haemostasis	W0103020702 / 30590 B-CTRL-P6001-010H7
14	P6101-010	TEControl A	10x1ml	Control plasma for haemostasis	W0103020702 / 30590 B-CTRL-P6101-010HQ
15	P6201-010	TEControl A Plus	10x1ml	Control plasma for haemostasis	W0103020702 / 30590 B-CTRL-P6201-010J9
16	P5001-010	TEClot Factor II	10x1ml	Coagulation factor ii (prothrombin)	W0103020202 / 30542 B-FAC-II-P5001-010ML
17	P5101-010	TEClot Factor V	10x1ml	Coagulation factor v	W0103020204 / 30544 B-FAC-V-P5101-010AN
18	P5201-010	TEClot Factor VII	10x1ml	Coagulation factor vii	W0103020205 / 30545 B-FAC-VII-P5201-0107B
19	P5301-010	TEClot Factor VIII	10x1ml	Coagulation factor viii	W0103020207 / 30547 B-FAC-VIII-P5301-01097
20	P5401-010	TEClot Factor IX	10x1ml	Coagulation factor ix	W0103020208 / 30548 B-FAC-IX-P5401-0106C
21	P5501-010	TEClot Factor X	10x1ml	Coagulation factor x	W0103020209 / 30549 B-FAC-X-P5501-010EQ
22	P5601-010	TEClot Factor XI	10x1ml	Coagulation factor xi	W0103020210 / 30551 B-FAC-XI-P5601-010A8
23	P5701-010	TEClot Factor XII	10x1ml	Coagulation factor xii	W0103020211 / 30552 B-FAC-XII-P5701-010CJ

(Recital 23 of Directive 98/79/EC on In Vitro Diagnostics Medical Devices) - Annex A - general IVD



Quality Management
We are certified
Voluntary participation in regular
monitoring according to ISO 9001:2008



TECO

MEDICAL INSTRUMENTS
PRODUCTION+TRADING GMBH
Dieselstraße 1
D-84088 Neufahrn N.B.
fon: +49-8773/707 80-0
fax: +49-8773/707 80-29

CERTIFICATE

for: **Mr. Vitalie Goreacii**

Company: **Sanmedico SRL**
Str. Petricani 88/1, oficiul 10
Chisinau - Rep. Moldava MD-2059
MOLDOVA

have participated with success at the intensive training session:

Application and technical training for following instruments:

- **Coatron X series**
 - **Installation**
 - **Application**
 - **General use, also in combination with TECAM Software**
 - **Technical and After Sales Service**

Supervisors: **Mr. Chr. Hoetzi and Mrs. Wendy Guo**

Place of Training: **TECO – Germany**

Date: **November 18th, 2019**



Christian Hoetzi
General Manager



TOP
INNOVATION
2017 - 2018

Clotting
Chromogenic
Immunturbidimetric

Coatron

Semi-automated
Coagulation Analyzer Series

With 1, 2 or 4 optical channels



TECO

Innovation in Coagulation

A new area of manual and semi-automated Coagulation Analyser rise up

The Coatron X instrument line is a consequent continuation in the development of the Coatron product line. Over 25 years in experience and innovation is the reference for our new Coatron X instrumentation line.

The unique detection principle in combination with the high-level analytical algorithm calculates exact, precise and reproducible results.

Easy in operation – self instructing user dialogue - reliable

Highest optical resolution, enlarged optic range, smallest sample and reagent volume

0.1 mOD, 0 - 3800 mOD, just with 75 µL sample and reagent volume

Complete optical analysis

No further parts required, like balls, stirrers etc.

Adaptation of the light level

Automatic light level adjustment of the optic channels to each sample

Exclusion of disturbance

Stray light reduction, exact temperature control, all parameter are preset

“Complete range of Coagulation Analysis with the highest standard and reliability. The new generation of Coagulation instruments with optical detection are here.”

Coatron X - product family



With 1, 2 or 4 optical channels.

www.teco-medical.com

Prepared for the daily routine and the upcoming requirements

One instrument – many possibilities

The Coatron X family is prepared to work with one, two or four channels. The built-up and functionality is specifically designed to each instrument version and requirements. The operation with the intuitive user dialogue and handling of the detection results are easy and effective. The possibility to connect the instrument to the **TECO Cloud** offers new perspective of instrument, reagent and consumables verification and handling. The precise and correct patient result is what we want to secure.



Quality is our basic demand

TECO develop and produce with qualified and specialized companies, located in Germany. High reliability, nearly maintenance free instruments are our benefit. Our reference is 25 years, in worldwide laboratories, with satisfied users.



TECO Cloud Services – A strong data bank and application service behind

All instrument versions of the Coatron X family are connectable via Bluetooth to Smart-devices, like mobile devices, tablets, etc. with a specific APP or direct access to the TECO Cloud Services.



Coatron	Eco	Pro	Top
General			
Dimensions	230 x 148 x 94 mm (l, b, h)		
Display	Colored touch display 4.3"		
Pre-warm temperature	37°C		
Pre-warm cuvettes (pcs.)	10	20	20
Pre-warm reagent 24mm (pcs.)	1	1	1
Pre-warm reagent 22mm (pcs.)	2	2	2
Pre-warm reagent 11mm (pcs.)	2	2	2
Reagent mixing position	-	1	1
Power values	110-240Vac, 50-60Hz / 5Vdc, 3.3A		
Interfaces			
RS232 (2x)	Printer, Barcode reader		
USB (2x)	Network, Firmware update		
Bluetooth	TECO Cloud, App		
Optic / tests			
Optic channels	1	2	4
Wavelength (nm)	620 (red)	405 (UV)	405 (UV)
Global Coag. tests	PT, APTT, TT, FIB		
Specific Coag. tests	-	individual factors	
Chromogenic Coag. tests	-	AT, PC	
Latex based tests	D-Dimer		
Whole blood tests	PT-B	-	-



The details make the difference

Coatron X


The remarkable details in every single component is achieved by selecting of premium suppliers.

The performance of a high level instrument is strongly depending on the concept in general and the perfect usability to reach the requirements of a modern laboratory analyser.

Priority No. 1 was to get a daily routine reliability and easy-to-use operation.

Software and connection possibilities

With the Coatron X product family starts a new time line in analysis management and service maintenance. Operation via intuitive, colored touchscreen, as well patient result management are perfectly optimized.



Operation details

Coatron	Eco	Pro	Top
Operation			
Touchscreen 4.3"	✓	✓	✓
Real time clock	✓	✓	✓
Stopwatch	✓	✓	✓
Language selection	✓	✓	✓
Interfaces			
USB to LIS	✓	✓	✓
Network to LIS (TECAM software required)	✓	✓	✓
Management			
Test calibration	✓	✓	✓
Tracking to Pat.ID, Patient ID, Sample ID or Auto ID	✓	✓	✓
Automatic optic start (no Starterpipette required)	✓	✓	✓
Double determination	✗	✓	✓
Sample management (ID)	✗	✓	✓
Reagent management (ID) (lot und expiry)	✗	✓	✓
Internal result databank	✗	✓	✓
Patient identification with barcode		optional	



Intuitive operation and control

Clear and easy to operate user dialogue with a high quality colored touchscreen

- Direct usable
- Short learning phase
- Logic, intuitive operation
- Reliable touchscreen surface
- Quick touch response



For small and mediate laboratory requirements

Concept is suitable for daily routine work in Coagulation laboratories and hospitals

- Three different versions available, depending on number of samples per day
- In maximum up to 4 optic channels available

Interfaces

RS232 (2x)

- For external serial printer and external barcodereader

LIS/USB

Bluetooth



Integrated barcode scan for reagents.





TECO Cloud Services

A strong data bank and application service behind

All instrument versions of the Coatron X family are connectable via Bluetooth to Smart-devices, like mobile devices, tablets, etc. with a specific APP or direct access to the TECO Cloud Services.



For trading partners worldwide, please visit our web-page

TECO Medical Instruments Production + Trading GmbH
Dieselstr. 1, 84088 Neufahrn, Germany
Tel.: +49 (0) 8773 70780-0, Fax +49 (0) 8773 70780-29
info@teco-gmbh.com, www.teco-medical.com

TECO
Innovation in Coagulation



IVD

REF

A0230-010, A0230-040, A0230-100,

Intended Use

This product is used for the determination of prothrombin time (PT) in plasma according to Quick^{1,2}. The test is sensitive to the extrinsic pathway coagulation factors II, V, VII, X and fibrinogen and therefore used for oral anticoagulant therapy with Vitamin-K inhibitors like Warfarin or Marcumar and also for the quantitative determination of extrinsic coagulation factors. The PT measures the extrinsic clotting time (factor VII activation) of test plasma after the addition PT reagent.

Contents & Determinations

Product	TECLOT PT-S	TECLOT PT-S	TECLOT PT-S
Cat.No.	A0230-010	A0230-040	A0230-100
PT-S Reagent*	5x2 mL	10x4 mL	10x10 mL

Determinations

Coatron M**	200 Det.	800 Det.	2000 Det.
Coatron A4	100 Det.	400 Det.	1000 Det.
Coatron A6	200 Det.	800 Det.	2000 Det.

*contains an extract of Rabbit brain with buffer, stabilizers and Calcium chloride.

**Micro method (75µL in total)

Preparation

Reconstitute with high purity water with the volume stated on the vial label.

A0230-010	A0230-040	A0230-100
2 mL	4 mL	10 mL

Let stand at room temperature with occasional swirling for at least 15 min. Then place reagent into instrument and let incubate for further 15 min. The reagent sediments and must be swirled before each testing. On Coatron instruments, you can use a mixing bar for this.

Storage & Stability

Unopened reagents are stable until the expiration date shown on the label stored at 2°-8°C. Opened reagent:

	2-8 °C	20-25 °C	37°C
PT Reagent	5 days	36 hours	8 hours

Precautions

Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material. All components are checked for HIV, HBV, HCV. However products from human blood should be considered as potentially infectious.

Specimen collection and storage⁴

- Obtain venous blood by clean vein puncture.
- Immediately mix 9 parts blood with 1 part 3.2% sodium citrate (0.105M) and mix well
- Centrifuge the specimen at 1500g for 10 min. (platelet < 10000/µL)
- Separate plasma after centrifugation and store in plastic or siliconised glass tube.
- Use plasma within 4 hours, otherwise store frozen and thaw just prior to use.

Stability of plasma: 4h at 18-26°C 8h at 2-8° 30d at -20°C 6m at -70°C

Procedure**A. Automated Method: Coatron A**

Prothrombin Time		A4		A6				A4		A6	
PAT	Patient	50µl	CP1	25µl	CP1	Incubation	0s	SENS	2		
BUF	IBS Buffer	0µl	P39	0µl	P79	Maxtime	120s	POINTS	4		
CLR	-	0µl	-	0µl	-	Unit	251	MIX	No		
DP	-	0µl	P00	0µl	P00	Method	Coag	Clean	0	0	
R0	-	0µl	P00	0µl	P00	Math	log XY	Multi	1	3	
R1	-	0µl	P00	0µl	P00	CT-Mech	No	S-Corr	0%		
R2	PT Reagent	100µl	P25	50µl	P46	Deadtime	7s	T-Corr	30% - 4s		

B. Manual Method: Coatron M system

- Incubate PT reagent at 37°C for at least 10 minutes
- Pipette 25 µl of sample into a test cuvette. Incubate at 37°C for 1-2 minutes.
- Add 50 µl of PT reagent (37°C) and simultaneously start test.
- Record the clotting time in seconds.

For other instrument, please refer to your instrument manual for more detailed instrument specific instructions.

Symbol keys

	Expiry date		In Vitro Diagnostica		Biological hazard		Catalogue Number		Reconstitute with dest. water		Consult accompanying documents
	Store at 2-8°C		EU conformity		Manufacturer		Lot. Number		Ready to use		Authorized Representative

Expected Results

Typical seconds: 11 – 18 sec
Normal range: 70 - 130% 0.85 – 1.15 INR

However results are influenced by instruments, technique, calibration etc. Each laboratory is recommended to establish its own range on the specific instrument used.

Standardisation and Calibration

The PT result is expressed as seconds or activity (% Quick) or INR (International Normalised Ratio).

INR results:

were calculated from normal time and ISI value (international sensitivity index). First is obtained by running fresh plasma from a pool of healthy individuals. The ISI value is stated in the LOT specific certificate of analysis.

$$INR = \left(\frac{Patient\ PT}{Normal\ PT} \right)^{ISI}$$

Activity % (Quick) result:

were calculated from a calibration curve, which is prepared from reference plasma (e.g. TECAL N) and dilutions in saline solution like 0.9% NaCl₂ or TECLOT IBS buffer. At least three or more calibration points are recommended. The calibration curve must be confirmed with control plasma in normal and abnormal range.

% of normal	100%*	50%	25%	12.5%**
diluted in saline	not dil.	1+1	1+3	1+7

*The median of at least 21 healthy individuals is defined as 100%.⁵

**12.5% dilution may cause "+++" results in some cases, because the level of fibrinogen is too high diluted for optical detection.

Quality Control

TEControl or other commercial control plasma should be used for reliable quality control of performance at a frequency in accordance with good laboratory practice (GLP). TEControl can be frozen one time after reconstitution. 120-150 µl stored in closed polypropylen tubes at -20°C is stable for 30 days

Limitations

Great care must be taken to minimize variations which may occur by seemingly insignificant factors.

A. Specimen Collection. AVOID:

- Use only plastic tubes or siliconised glass.
- Delayed mixing of blood with anticoagulant.
- Contamination with tissue thromboplastin.
- Improper ratio of anticoagulant with blood.
- Hemolyzed, icteric or lipemic samples may interfere optical systems

B. Laboratory Techniques

- Perform tests at 37°C.
- Use only high purity water.
- Optimum pH is 7.0-7.5.
- ISI value is not constant within the first 30 min after reconstitution.
- Reagent sediments and must be swirled before each testing.

Performance Characteristics**Typical performance on instrument Coatron M4**

Precision: CV% (within run) CV% (inter-runs)
Normal control < 3.0 < 5.0
Abnormal control < 3.0 < 5.0

Warranty

This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

References

- Quick, A.J., The Hemorrhagic Diseases and the Physiology of Hemostasis. Charles C. Thomas: Springfield, IL. 1942.
- Quick, A.J., Hemorrhagic Diseases. Lea and Febiger: Philadelphia. 1957.
- Miale, J.B., Laboratory Medicine-Hematology, 4th Edition. C.V. Mosby: St. Louis. 1972.
- National Committee for Clinical Laboratory Standards: Guidelines for the Standardized Collection, Transport and Preparation of Blood Specimens for Coagulation Testing and Performance of Coagulation Assays.
- Besselaar A M H P van den, Lewis SM, Mannucci P n Poller L. 1993. Status of present and candidate International Reference Preparations (IRP) of thromboplastin for prothrombin time. Thromb Hemostas 69; 85
- Besselaar A M H P van den. 1991. The significance of the International Normalized Ratio (INR) for oral anticoagulant therapy. H17CC 3; 146153.



IVD

REF

A0501-010, A0501-025, A0511-020, A0511-050

Intended Use

The TEClot FIB is intended for the quantitative determination of fibrinogen in human plasma according to method developed by Clauss.¹ Levels of fibrinogen can increase as a result of inflammation, pregnancy or oral contraceptive use². Decreased levels can be found in certain states such as liver disease and DIC. Congenital deficiencies include afibrinogenemia (no detectable fibrinogen), hypofibrinogenemia (<1 mg/ml) and dysfibrinogenemia (abnormal fibrinogen molecule).

Contents & Preparation

Product	TEClot FIB Kit-10	TEClot FIB Kit-25	TEClot FIB	TEClot FIB
Cat.No.	A0501-010	A0501-025	A0511-020	A0511-050
Thrombin Reagent	5x2 mL	5x5 mL	10x2 mL	10x5 mL
IBS Buffer	1x125 mL	1x125 mL	-	-
TECal Normal	1x1 mL	1x1 mL	-	-
TEControl A	1x1 mL	1x1 mL	-	-

Determinations

Coatron M*	400 Det.	1000 Det.	800 Det.	2000 Det.
Coatron A4	200 Det.	500 Det.	400 Det.	1000 Det.
Coatron A6	200 Det.	500 Det.	400 Det.	1000 Det.

*Micro method (75µl in total)

- Thrombin Reagent:
Contains bovine thrombin (~80NIH) with stabilizers
REF: A0501-010/A0511-020: Reconstitute with 2mL purified water
REF: A0501-025/A0511-050: Reconstitute with 5mL purified water
- IBS Buffer: Ready to use. Contains Imdazole buffered saline
- TECal Normal: Reconstitute with 1 mL purified water.
Contains citrated human plasma.
- TEControl A: Reconstitute with 1 mL purified water.
Contains citrated human plasma.



Swirl gently after reconstitution and allow standing for 15 minutes at room temperature. Mix well before use. Do not shake.

Storage & Stability

Unopened reagents are stable until the expiration date shown on the label stored at 2°-8°C. Opened reagent:

Thrombin Reagent*	2-8 °C	15-25 °C	37 °C
	12 days	5 days	24 hours
TEControl or Plasma	2-8 °C	15-25 °C	-20 °C
	8 hours	4 hours	30 days

* Reagent must be protected from UV-light and evaporation

Precautions

Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material. All components are checked for HIV, HBV, HCV. However products from human blood should be considered as potentially infectious.

Specimen collection and storage³

- Obtain venous blood by clean vein puncture.
- Immediately mix 9 parts blood with 1 part 3.2% sodium citrate (0.105M) and mix well
- Centrifuge the specimen at 1500g for 10 min. (platelet < 10000/µL)
- Separate plasma after centrifugation and store in plastic or siliconised glass tube.
- Use plasma within 4 hours, otherwise store frozen and thaw just prior to use.

Procedure

A. Automated Method. Coatron A

Fibrinogen		A4		A6				A4		A6	
PAT	Patient	10µl	CP1	10µl	CP1	Incubation	0s	SENS	0		
BUF	IBS Buffer	90µl	P39	90µl	P79	Maxtime	120s	POINTS	4		
CLR	-	0µl	-	0µl	-	Unit	769	MIX	No		
DP	-	0µl	P00	0µl	P00	Method	Coag	Clean	1	3	
R0	-	0µl	P00	0µl	P00	Math	log XY	Multi	1	1	
R1	-	0µl	P00	0µl	P00	CT-Mech	Yes	S-Corr	0%		
R2	Fibrinogen	50µl	P29	50µl	P49	Deadtime	3s	T-Corr	0%		

B. Manual Method: Coatron M

- Preparation of Standard, Control and Patient Dilutions

Standard Dilution	Plasma	IBS Buffer
1:5	200µL Standard	800µL
1:10	500µL 1:5 STD	500µL
1:20	500µL 1:10 STD	500µL
1:40	500µL 1:20 STD	500µL
Patient or Control	100µL Plasma	900µL

- Pipette **50 µl diluted standard or patient plasma** (1:10) into a test cuvette. Prewarm at 37°C for 1-2 minutes.

- Add **25 µl Thrombin reagent** and simultaneously start test.

For other instrument, please refer to your instrument manual for more detailed instrument specific instructions.

Calibration

TECal Normal or other commercially prepared plasma standard in which Fibrinogen has been determined should be used as reference (200-300mg/dL). Plot the clotting time obtained with each of the FIB standard dilutions on the y-axis against the concentration of FIB (mg/dL) on the x-axis using log-log graph paper. The line of best fit should be determined by linear regression analysis. The fibrinogen in plasma samples can be determined by interpolation from the calibration curve.

Expected Results

Typical normal results are 180-450 mg/dL^{4,5}. However results are influenced by the method of clot detection and can vary from laboratory to laboratory. Each laboratory is recommended to establish its own normal range on the specific instrument used.

Quality Control

TEControl or other commercial control plasma should be used for reliable quality control of performance at a frequency in accordance with good laboratory practice (GLP). TEControl can be frozen one time after reconstitution. 120-150 µl stored in closed polypropylen tubes at -20°C is stable for 30 days

Limitations

- Specimen Collection. AVOID:
 - Use only plastic tubes or siliconised glass.
 - Delayed mixing of blood with anticoagulant.
 - Contamination with tissue thromboplastin.
 - Improper ratio of anticoagulant with blood.
 - Hemolyzed, icteric or lipemic samples may interfere optical systems
- Laboratory Techniques
 - Perform tests at 37°C.
 - Use only high purity water.
 - Optimum pH is 7.0-7.5.

Performance Characteristics

Precision:	CV% (within run)	CV% (inter-runs)
Normal control	< 5.0	< 5.0
Abnormal control	< 5.0	< 10.0

(Typical performance on instrument Coatron M4)

Warranty

This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

References

- Clauss, A., Gerinnungsphysiologische Schnellmethode zur bestimmung des Fibrinogens. Acta Haematol., 1957, 17: 237-246.
- Shaw, T.S., Assays for Fibrinogen and its Derivatives, CRC Crit. Rev. Clin. Lab. Sci., 1977, 8: 145-192.
- National Committee for the National Laboratory (NCCLS) Standards: Collection transport and preparation of blood specimens for coagulation testing and performance of coagulation assays. Document H21-A2, vol. 11, No. 23, 1991.
- Scully, R.E. et al., Normal Reference Laboratory Values, N. Eng. J. Med., 1980, 302(37) : 37-48.
- Okuno, T. and Selenko, V., Amer. J. Med. Tech., 1972, 38(6) : 196-201.

Symbols key:

Expiry date	In Vitro Diagnostica	Biological hazard	Catalogue Number	Consult accompanying documents
Store at 2-8°C	EU conformity	Manufacturer	Lot. Number	Authorized Representative



IVD

REF

A0501-010, A0501-025, A0511-020, A0511-050

Verwendungszweck

TEClot FIB wird zur quantitativen Bestimmung von Fibrinogen im menschlichen Plasma nach einer von Clauss¹ entwickelten Methode verwendet. Der Fibrinogenpegel kann auf Grund von Entzündungen, Schwangerschaft und dem Gebrauch von Ovulationshemmern ansteigen². Geringere Konzentrationen können bei verschiedenen Krankheiten wie Leberversagen und DIC auftreten. Angeborene Defizite beinhalten Afibrinogenämie (kein auffindbares Fibrinogen), Hypofibrinogenämie (<1 mg/ml) und Dysfibrinogenämie (abnormale Fibrinogenmoleküle).

Inhalte und Vorbereitungen

Produkt	TEClot FIB Kit-10	TEClot FIB Kit-25	TEClot FIB	TEClot FIB
Kat. Nr.	A0501-010	A0501-025	A0511-020	A0511-050
Thrombin Reagenz	5x2 mL	5x5 mL	10x2 mL	10x5 mL
IBS Puffer	1x125 mL	1x125 mL	-	-
TECal Normal	1x1 mL	1x1 mL	-	-
TEControl A	1x1 mL	1x1 mL	-	-

Bestimmungen

	400 Def.	1000 Def.	800 Def.	2000 Def.
Coatron M*				
Coatron A4	200 Def.	500 Def.	400 Def.	1000 Def.
Coatron A6	200 Def.	500 Def.	400 Def.	1000 Def.

*Mikromethode (75µL insgesamt)

- Thrombin Reagenz:
Enthält Rinderthrombin (~80 NIH) mit Stabilisatoren.
REF: A0501-010/A0511-020: mit 2ml hochreinem Wasser anlösen
REF: A0501-025/A0511-050: mit 5ml hochreinem Wasser anlösen
- IBS Puffer: gebrauchsfertig, 125ml
Enthält gepufferte Natriumchlorid Lösung, pH 7,3-7,4
- TECal Normal: Mit 1ml hochreinem Wasser anlösen
Enthält mit Zitrat versetztes menschliches Plasma.
- TEControl A: Mit 1ml hochreinem Wasser anlösen
Enthält mit Zitrat versetztes menschliches Plasma.

Nach der Anlösung vorsichtig leicht schwenken und bei Raumtemperatur 15 Minuten stehen lassen. Vor Gebrauch gut mischen. Nicht schütteln.

Lagerung und Stabilität

Ungeöffnete Reagenzien sind bei Lagerung zwischen 2-8°C bis zum auf dem Etikett angegebenen Verfallsdatum haltbar. **Geöffnete Reagenzien:**

Thrombin Reagenz*	2-8 °C	15-25 °C	37 °C
	12 days	5 days	24 Std
TEControl oder Plasma	2-8 °C	15-25 °C	-20 °C
	8 Std	4 Std	30 Std

* Reagenz muss vor UV-Licht und Verdunstung geschützt werden.

Vorsichtsmaßnahme

Haut- & Augenkontakt vermeiden. Abfälle gemäß lokaler Richtlinien für infektiöse Materialien entsorgen. Alle Bestandteile wurden auf HIV, HBV und HCV getestet. Trotzdem müssen Produkte aus menschlichem Blut immer als potentiell infektiös behandelt werden.

Probenentnahme und Lagerung³

- Venöses Blut mittels Venenpunktur unter sauberen Bedingungen entnehmen.
- Sofort 9 Teile Blut mit einem Teil 3,2% Natriumzitrat (0,105M) gut mischen.
- Probe bei 1500g 10 Minuten lang zentrifugieren (Thrombozyten <10000/µl)
- Plasma nach der Zentrifugation entfernen und in einem Röhrchen aus Plastik oder silikonisiertes Glas aufbewahren.
- Plasma innerhalb von 4 Stunden verwenden, andernfalls gefroren lagern und kurz vor Gebrauch auftauen.

Verfahren

A. Automatenmethode: Coatron A

Fibrinogen		A4		A6				A4		A6	
PAT	Patient	10µl	CP1	10µl	CP1	Incubation	0s	SENS	0		
BUF	IBS Buffer	90µl	P39	90µl	P79	Maxtime	120s	POINTS	4		
CLR	-	0µl	-	0µl	-	Unit	769	MIX	No		
DP	-	0µl	P00	0µl	P00	Method	Coag	Clean	1	3	
R0	-	0µl	P00	0µl	P00	Math	log XY	Multi	1	1	
R1	-	0µl	P00	0µl	P00	CT-Mech	Yes	S-Corr	0%		
R2	Fibrinogen	50µl	P29	50µl	P49	Deadtime	3s	T-Corr	0%		

Erklärung der Symbole:

Verfallsdatum	In-Vitro Diagnostik	Biologische Gefahr	Katalog-Nummer	Begleitpapiere beachten
Bei 2-8°C lagern	EU Konformität	Hersteller	Lot.-Nummer	Bevollmächtigter

B. Manuelle Methode: Coatron M

- Vorbereitung von Standard-, Kontroll- und Patientenlösungen

Standardlösung	Plasma	IBS Puffer
1:5	200µL Standard	800µL
1:10	500µL 1:5 STD	500µL
1:20	500µL 1:10 STD	500µL
1:40	500µL 1:20 STD	500µL
Patient oder Kontrolle	100µL Plasma	900µL

- 50µl verdünntes Standard- oder Patientenplasma (1:10) in eine Küvette pipettieren. Bei 37°C für 1-2 Minuten erwärmen
 - 25µl Thrombinreagenz hinzufügen und gleichzeitig Test starten.
- Wenn Sie ein anderes Gerät verwenden, lesen Sie bitte für genauere Informationen die entsprechende Geräteanleitung.

Kalibrierung

TECal Normal oder anderes kommerzielles Standardplasma, mit bekanntem Fibrinogengehalt, sollte als Referenz (200-300 mg/dl) verwendet werden. Geben Sie die Gerinnungszeit jeder FIB Standard Lösung auf der Y- Achse gegen die FIB Konzentration (mg/dl) auf der X- Achse an. Verwenden Sie Millimeterpapier. Die Reihe der besten Ergebnisse sollte durch lineare Regressionsanalyse bestimmt werden. Fibrinogen in den Plasmaproben kann durch Interpolation der Kalibrierungskurve bestimmt werden.

Erwartete Ergebnisse

Typische normale Ergebnisse sind 180-450mg/dl^{4,5}. Die Ergebnisse sind jedoch von der Methode, wie die Gerinnungszeit bestimmt wird, abhängig und können von Labor zu Labor variieren. Jedem Labor wird empfohlen, seinen eigenen normalen Ergebnisbereich auf dem verwendeten Instrument zu erstellen.

Qualitätskontrolle

TEControl oder anderes kommerzielles Kontrollplasma sollte, um eine gute Qualität sicherzustellen, in regelmäßigen Abständen entsprechend Laborrichtlinien gemessen werden. In regelmäßigen Abständen entsprechend Laborrichtlinien gemessen werden. TEControl kann einmalig wieder eingefroren werden. Hierfür 120-150µl in einem verschließbaren polypropylen Gefäß bei -20°C aufbewahren und innerhalb der nächsten 30 Tage verwenden.

Beschränkungen

- Probenvorbereitung. Achten Sie auf:
 - nur Plastikröhrchen oder silikonisiertes Glas verwenden
 - verzögertes Mischen von Blut mit Antikoagulanzen vermeiden
 - Kontamination mit Gewebethromboplastin vermeiden
 - falsches Verhältnis von Antikoagulanzen und Blut vermeiden
 - Hämolytische, lipämische oder ikterische Proben können optische Systeme stören
- Labortechniken
 - Tests bei 37°C durchführen
 - nur hochreines Wasser verwenden
 - der optimale pH Wert ist 7,0-7,5

Leistungsdaten

Präzision:	VK% (Einzelauf)	VK% (Mehrfachlauf)
Normale Kontrolle	< 5,0	< 5,0
Abnormale Kontrolle	< 5,0	< 10,0

(Typische Leistung beim Gerät Coatron M4)

Garantie

Es wird garantiert, dass die Wirkungsweise dieses Produktes den Angaben auf der Packung und in der Produktliteratur entspricht. TECO haftet weder für die Veräußerlichkeit oder Eignung dieses Produktes für irgendwelche andere Zwecke noch für irgendwelche Folgeschäden, die sich aus der vorstehenden, expliziten Garantie ergeben.

Referenzen

- Clauss, A., Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol., 1957, 17: 237-246.
- Shaw, T.S., Assays for Fibrinogen and its Derivatives, CRC Crit. Rev. Clin. Lab. Sci., 1977, 8: 145-192.
- National Committee for the National Laboratory (NCCLS) Standards: Collection transport and preparation of blood specimens for coagulation testing and performance of coagulation assays. Document H21-A2, vol. 11, No. 23, 1991.
- Scully, R.E. et al., Normal Reference Laboratory Values, N. Eng. J. Med., 1980, 302(37): 37-48.
- Okuno, T. and Selenko, V., Amer. J. Med. Tech., 1972, 38(6): 196-201.



IVD

REF

A0501-010, A0501-025, A0511-020, A0511-050

Revisions-Übersicht:

Rev.	am	Änderung durch	Gültig für	Freigabe am	Freigabe durch
1	5.4.11	WG	Technoclone FIB		
	Beschreibung:	New box insert for Technoclone FIB.			
2	21.12.11	CB	Technoclone FIB	21.12.11	CH
	Beschreibung:	Neue Stabilitätsangaben. Die Vorgaben wurden dem Technoclone Stability Test Report „TC6E0C.01“ vom 5.5.2010 entnommen.			
3	11.11.13	CB	Technoclone FIB		
	Beschreibung:	<ul style="list-style-type: none"> - Protokoll für A4+A6 - Stabilitätsdaten neu 			
4	16.10.17	AR	Technoclone FIB	16.10.17	CH
	Beschreibung:	Technoclone Puffer (A0591-090) wird ersetzt durch IBS (A0590-125) (wegen deutlicher Messunterschiede bei Coatron A und X Serie) Wertermittlung für das CoA erfolgt ebenso mit IBS (A0590-125)			
5	23.01.18	VG	Technoclone FIB	23.01.18	VG
	Beschreibung:	Neue Stabilitätsangaben von Technoclone vom Thrombin Reagent.			





IVD

REF

A0590-125

Intended Use

The IBS Buffer solution is optimally formulated for use on Coagulation Analyzers. Use in accordance with the recommended Operators Manuals for installing and replacing Owrens Veronal Buffer (OVB). The IBS can be used as the diluent for preparing plasma dilutions in the performance of Fibrinogen determinations and Coagulation Factor Assays with all manual, mechanical, or photo-optical means of clot detection. Follow Reagent manufacturer's recommended procedures for preparation of plasma dilutions using Imidazole Buffered Saline.

Contents & Determinations

Product	IBS Buffer
Cat.No.	A0590-125
IBS Buffer	1x125 mL

Preparation

IBS: pH 7.3 - 7.4, liquid
Ready to use.

Storage and Stability

Unopened reagents are stable until the expiration date shown on the label stored at 2-8°C.

Precautions

Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material.

Warranty

This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

Symbols key:

Expiry date	In Vitro Diagnostica	Biological hazard	Catalogue Number	Consult accompanying documents
Store at 2-8°C	EU conformity	Manufacturer	Lot. Number	Authorized Representative



A0590-125

Verwendungszweck

Die IBS Pufferlösung (Imidazole Buffered Saline) wird für die Verdünnung von Plasma verwendet werden, wie es z.B. bei der koagulometrischen Bestimmung von Fibrinogen, Einzelfaktoren oder auch Verdünnungsreihen für die Methoden Kalibrierung notwendig ist.

Inhalte und Bestimmungen

Produkt	IBS Puffer
Kat.Nr.	A0590-125
IBS Buffer	1x125 mL

Vorbereitung

IBS: pH 7.3 - 7.4, flüssig
Gebrauchsfertig

Lagerung und Stabilität

Ungeöffnete Reagenzien sind bei Lagerung zwischen 2-8°C bis zum auf dem Etikett angegebenen Verfallsdatum haltbar.

Vorsichtsmaßnahmen

Haut- und Augenkontakt vermeiden. Angemessene Schutzkleidung tragen. Bestandteile gemäß lokaler Vorschriften für infektiöse Materialien entsorgen.

Garantie

Es wird garantiert, dass die Wirkungsweise dieses Produktes den Angaben auf der Packung und in der Produktliteratur entspricht. TECO haftet weder für die Verkäuflichkeit oder Eignung dieses Produktes für irgendwelche andere Zwecke noch für irgendwelche Folgeschäden, die sich aus der vorstehenden, expliziten Garantie ergeben.

Erklärung der Symbole:

Verfallsdatum	In-Vitro Diagnostik	Biologische Gefahr	Katalog-Nummer	Begleitpapiere beachten
Bei 2-8°C lagern	EU Konformität	Hersteller	Lot. - Nummer	Bevollmächtigter



IVD

REF

P6001-010

Intended Use

Use as a normal control for following coagulation tests:

**PT, APTT, Thrombin time, Fibrinogen,
Anti-thrombin and D-Dimer**

Contents

10 x 1mL freeze dried citrate-anticoagulated human plasma

Preparation

Reconstitute individual vials with **1,0 ml** distilled water. Allow to stand at room temperature, with occasional swirling, for 15 min before use. Be certain all particulate matter is well dissolved.

PT whole blood (TEClot PT-B): Reconstitute individual vials with **1,7 ml** distilled water.

Storage & Stability

Unopened vials are stable until the expiration date shown on the label stored at 2°-8°C.

Dissolved plasma change analytic levels below 10% if stored as following:

-20 °C	2-8 °C	20-25 °C
1 month	8 hours	4 hours

Dissolved plasma can be refrozen only one time in aliquots (120-150µL). Stored at -20°C in closed polypropylene tubes, the aliquots must be used within 30 days.

Precautions

This product contains substance from human origin!
Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material. All components are checked for HIV, HBV and HCV. However products from human blood should be considered as potentially infectious.

Expected Results

Refer to "Certificate of Analysis".

Warranty

This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

Symbols key:

Expiry date	In Vitro Diagnostica	Biological hazard	Catalogue Number	Consult accompanying documents
Store at 2-8°C	EU conformity	Manufacturer	Lot. Number	Authorized Representative





Verwendungszweck

Als normale Kontrolle für folgende Gerinnungstests verwenden:

**PT, APTT, Thrombinzeit, Fibrinogen,
Antiithrombin und D-Dimer**

Inhalt

10 x 1mL gefriergetrocknetes mit Zitrat versetztes gerinnungshemmendes Humanplasma

Vorbereitung

Die einzelnen Fläschchen mit 1,0ml destilliertem Wasser anlösen. Fläschchen bei Raumtemperatur bis zur Anwendung unter gelegentlichen Verwirbeln 15 Minuten lang stehen lassen. Stellen Sie sicher, dass alle Partikel gut aufgelöst sind.

Vollblut PT (TEClot PT-B): einzelne Fläschchen mit 1,7ml destilliertem Wasser anlösen.

Lagerung und Stabilität

Ungeöffnete Fläschchen sind bei Lagerung zwischen 2-8°C zum bis auf dem Etikett angegebenen Verfallsdatum haltbar.

Gelöstes Plasma verändern die analytischen Levels unter 10% wenn wie folgt gelagert:

-20 °C	2-8 °C	20-25 °C
1 Monat	8 Stunden	4 Stunden

Gelöstes Plasma kann einmalig wiedereingefroren werden. Die Aliquots (120-150µL) sind 30 Tage haltbar, wenn sie in polypropylen Gefäßen bei -20°C aufbewahrt werden.

Vorsichtsmaßnahmen

Dieses Produkt enthält Substanzen humanen Ursprungs! Haut- und Augenkontakt vermeiden. Angemessene Schutzkleidung tragen. Abfälle laut lokaler Regelungen für infektiöse Materialien entsorgen. Alle Bestandteile wurden auf HIV, HBV und HCV getestet. Trotzdem müssen Produkte aus menschlichem Blut immer als potentiell infektiös angesehen werden.

Erwartete Ergebnisse

Lesen Sie das Analysenzertifikat

Garantie

Es wird garantiert, dass die Wirkungsweise dieses Produkts den Angaben auf der Packung und in der Produktliteratur entspricht. TECO haftet weder für die Verkäuflichkeit oder Eignung dieses Produktes für irgendwelche andere Zwecke noch für irgendwelche Folgeschäden, die sich aus der vorstehenden, expliziten Garantie ergeben.

Erklärung der Symbole:

Verfallsdatum	In-Vitro Diagnostik	Biologische Gefahr	Katalog-Nummer	Begleitpapiere beachten
Bei 2-8°C lagern	EU Konformität	Hersteller	Lot. - Nummer	Bevollmächtigter





IVD

REF

P6101-010

Intended Use

Use as an abnormal control for following coagulation tests:

**PT, APTT, Thrombin time, Fibrinogen,
Antithrombin and D-Dimer**

Contents

10 x 1mL freeze dried citrate-anticoagulated human plasma

Preparation

Reconstitute individual vials with **1,0 ml** distilled water. Allow to stand at room temperature, with occasional swirling, for 15 min before use. Be certain all particulate matter is well dissolved.

PT whole blood (TEClot PT-B): Reconstitute individual vials with **1,7 ml** distilled water.

Storage & Stability

Unopened vials are stable until the expiration date shown on the label stored at 2°-8°C.

Dissolved plasma change analytic levels below 10% if stored as following:

-20 °C	2-8 °C	20-25 °C
1 month	8 hours	4 hours

Dissolved plasma can be refrozen only one time in aliquots (120-150µL). Stored at -20°C in closed polypropylene tubes, the aliquots must be used within 30 days.

Precautions

This product contains substance from human origin!
Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material. All components are checked for HIV, HBV and HCV. However products from human blood should be considered as potentially infectious.

Expected Results

Refer to "Certificate of Analysis".

Warranty

This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

Symbols key:

Expiry date	In Vitro Diagnostica	Biological hazard	Catalogue Number	Consult accompanying documents
Store at 2-8°C	EU conformity	Manufacturer	Lot. Number	Authorized Representative





IVD

REF

P6101-010

Verwendungszweck

Als abnormale Kontrolle für folgende Gerinnungstests verwenden:

**PT, APTT, Thrombinzeit, Fibrinogen,
Antithrombin und D-Dimer**

Inhalt

10 x 1mL gefriergetrocknetes mit Zitrat versetztes gerinnungshemmendes Humanplasma

Vorbereitung

Die einzelnen Fläschchen mit 1,0ml destilliertem Wasser anlösen. Fläschchen bei Raumtemperatur bis zur Anwendung unter gelegentlichen Verwirbeln 15 Minuten lang stehen lassen. Stellen Sie sicher, dass alle Partikel gut aufgelöst sind.

Vollblut PT (TEClot PT-B): einzelne Fläschchen mit 1,7ml destilliertem Wasser anlösen.

Lagerung und Stabilität

Ungeöffnete Fläschchen sind bei Lagerung zwischen 2-8°C zum bis auf dem Etikett angegebenen Verfallsdatum haltbar.

Gelöstes Plasma verändern die analytischen Levels unter 10% wenn wie folgt gelagert:

-20 °C	2-8 °C	20-25 °C
1 Monat	8 Stunden	4 Stunden

Gelöstes Plasma kann einmalig wiedereingefroren werden. Die Aliquots (120-150µL) sind 30 Tage haltbar, wenn sie in polypropylen Gefäßen bei -20°C aufbewahrt werden.

Vorsichtsmaßnahmen

Dieses Produkt enthält Substanzen humanen Ursprungs! Haut- und Augenkontakt vermeiden. Angemessene Schutzkleidung tragen. Abfälle laut lokaler Regelungen für infektiöse Materialien entsorgen. Alle Bestandteile wurden auf HIV, HBV und HCV getestet. Trotzdem müssen Produkte aus menschlichem Blut immer als potentiell infektiös angesehen werden.

Erwartete Ergebnisse

Lesen Sie das Analysenzertifikat

Garantie

Es wird garantiert, dass die Wirkungsweise dieses Produkts den Angaben auf der Packung und in der Produktliteratur entspricht. TECO haftet weder für die Verkäuflichkeit oder Eignung dieses Produktes für irgendwelche andere Zwecke noch für irgendwelche Folgeschäden, die sich aus der vorstehenden, expliziten Garantie ergeben.

Erklärung der Symbole:

Verfallsdatum	In-Vitro Diagnostik	Biologische Gefahr	Katalog-Nummer	Begleitpapiere beachten
Bei 2-8°C lagern	EU Konformität	Hersteller	Lot. - Nummer	Bevollmächtigter





ТОВ «ХЕМА» код ЄДРПОУ 36038442
Адреса 03179, м. Київ, вул. Академіка Єфремова, 23
Для кореспонденції: 03179, а/с 49
З питань замовлення продукції: 050-422-62-16, 067-422-62-16
Тел.: +38 (095) 60-99-555 Факс: +38 (044) 422-62-16
e-mail: info@xema.com.ua
www.xema.in.ua

STATEMENT

We, XEMA LLC, as a manufacturer of in vitro diagnostic medical devices, having a registered office at Akademika Yefremova St. 23, Kyiv, Ukraine assign SRL SANMEDICO having a registered office at A. Corobceanu Street 7A, apt. 9, Chişinău MD-2012, Moldova, as authorized representative in correspondence with legislative requirements of the Republic of Moldova.

We declare that the company mentioned above is authorized to register, notify, renew, or modify the registration of medical devices on the territory of the Republic of Moldova.

This Statement shall come into force on the date of its signing. The duration of this Statement is 3 years from the date of signing.

Date: 06.09.2023

Signature:

Director Xema LLC
Oleksandra Zavaliei



СЕРТИФІКАТ

про відповідність системи управління якістю

Зареєстрований у Реєстрі

«29» червня 2022 р.

№ UA.SM.214-21

Дійсний до «03» серпня 2024 р.

Перше видання: «04» серпня 2021 р.

ЦИМ СЕРТИФІКАТОМ ВІДПОВІДНОСТІ ПОСВІДЧУЄТЬСЯ,
ЩО СИСТЕМА УПРАВЛІННЯ ЯКОСТІ СТОСОВНО

проектування та розроблення, виробництва та дистрибуції
медичних виробів для діагностики *in vitro*

впроваджена:

ТОВ «ХЕМА»

за адресою: вул. Академіка Єфремова, 23, м. Київ, 03179, Україна

відповідає вимогам ISO 13485:2016;

ДСТУ EN ISO 13485:2018 (EN ISO 13485:2016, IDT; ISO 13485:2016, IDT).

Контроль відповідності сертифікованої системи управління якістю вимогам зазначеного стандарту здійснюється шляхом нагляду, періодичність і процедури якого регламентуються процедурами органу з оцінки відповідності.

Сертифікат видано Органом з оцінки відповідності ТОВ «УКРМЕДСЕРТ», акредитованим Національним агентством з акредитації України, атестат від 24.12.2019 № 80047, адреса: вул. Драгоманова, будинок 1-А, оф. 2, м. Київ, 02059, Україна, тел./факс: +38-067-595-02-30, <https://ukrmedcert.org.ua>.

Директор



І.М. Хотенюк



Certificate

Of Marketing Authorization of Medical Product

within Germany, the member states of the European Union
and the other states having a contractual agreement with the European Economic Area

Nr. **AR/IVD/XEMA LLC/01/2023**

Issued on the basis of the Declaration of conformity and registration taking into account Article 11 of Regulation (EU) 2017/746 (IVDR) on In Vitro Diagnostic, and Medical Device Implementing Act (MPDG)

Ausgestellt auf Grund der Konformitätserklärung und Registrierung unter Berücksichtigung der der Verordnung (EU) 2017/746 (IVDR) über In-vitro-Diagnostika und Medizinprodukte-Durchführungsgesetz (MPDG)

Manufacturer / Hersteller

XEMA LLC

SRN: UA-MF-000032959

UKRAINE, 03179 KYIV
Akademika Yefremova St. 23
qa@xema.com.ua; www.xema.in.ua

Product name / Produkt

See annex to the Certificate

Siehe Anhang zum Zertifikat

Product Classification:
Produktklassifizierung

In Vitro Diagnostic Medical Devices

In-vitro-Diagnostikum (IVD) Medizinprodukte

Category:
Kategorie

Common/ Other IVD

Sonstige IVD-Produkte

Conformity assessment procedure:
Konformitätsbewertungsverfahren:

**EC DECLARATION OF CONFORMITY
(Annex III, except point 6, Directive 98/79/EC)
in connection with article 110(3) IVDR**

EU- KONFORMITÄTSEKTLARUNG

(Anhang III, außer Nummer 6, Richtlinie 98/79 / EG)
in Verbindung mit Artikel 110 (3) IVDR

State Competent Authority:
Staatliche Zuständige Behörde

BfArM Federal Institute for Drugs and Medical Devices
DMIDS (German Medical Device Information and Database System)

BfArM Das Bundesinstitut für Arzneimittel und Medizinprodukte DMIDS
(Deutsches Medizinprodukte-Informations- und Datenbanksystem)

Date of issue : **2023-03-07**
Das Ausstellungsdatum

Valid to : **2025-05-31**
Gültig bis

Represented in the EC by:

Polmed.de Beata Rozwadowska
Fichtenstr. 12A, 90763 Fürth, Germany
email: info@polmed.de
Tel: +49 911 93163967



Polmed.de

SRN: DE-AR-000006947

Annex to the Certificate No.:

Anhang zum Zertifikat Nr.:

AR/IVD/XEMA LLC/01/2023

The following medical devices can be placed on the market in the Federal Republic of Germany, in the member states of the European Economic Community (EEC) and in the other contract states of the agreement about the European Economic Area.

Die folgenden Medizinprodukte in der Bundesrepublik Deutschland, in den Mitgliedsstaaten der Europäischen Wirtschaftsgemeinschaft (EG) und in den Vertragsstaaten der EG in den Verkehr gebracht werden dürfen.

#	Nomenclature term Nomenklaturbezeichnung	Catalog No. Katalog-Nr.	Name of device Produktbezeichnung	DMIDS Registration number Registriernummer
1.	ASPERGILLUS	K021	GalMAg EIA	DE/CA64/00115824
2.	HSV IgG	K104	HSV 1/2 IgG EIA	DE/CA64/00115826
3.	HSV IgM	K104M	HSV 1, 2 IgM EIA	DE/CA64/00115833
4.	HSV 2 IgG	K104B	HSV 2 IgG EIA	DE/CA64/00115836
5.	MYCOPLASMA ANTIBODY ASSAYS	K106	Mycoplasma IgG EIA	DE/CA64/00115837
6.	SYPHILIS ANTIBODY ASSAYS TOTAL	K111	anti-Treponema pallidum EIA	DE/CA64/00115839
7.	SYPHILIS ANTIBODY IGG	K111G	Treponema pallidum IgG EIA	DE/CA64/00115840
8.	H. PYLORI ANTIBODY ASSAYS	K119G	Helicobacter pylori IgG EIA	DE/CA64/00115850
9.	OTHER OTHER BACTERIOLOGY IMMUNOASSAY	K126	Ureaplasma IgG EIA	DE/CA64/00115851
10.	THYROID PEROXIDASE (INCL. MICROSOMAL) ANTIBODIES	K131	aTPO EIA	DE/CA64/00115852
11.	THYROGLOBULIN AUTOANTIBODIES	K132	aTG EIA	DE/CA64/00115853
12.	MPO ANCA	K133	aMPO EIA	DE/CA64/00115854
13.	TISSUE TRANSGLUTAMINASE ANTIBODIES	K160 K161	anti-TGlu IgG EIA anti-TGlu IgA EIA	DE/CA64/00115855
14.	GIARDIA LAMBLIA	K171	anti-Giardia lamblia EIA	DE/CA64/00115856
15.	OTHER PARASITOLOGY	K174	Ascaris IgG EIA	DE/CA64/00115857
16.	ECHINOCOCCUS	K175	Echinococcus IgG EIA	DE/CA64/00115858
17.	DISTOMATOSIS	K176	Opisthorchis IgG EIA	DE/CA64/00115859
18.	GLIADIN ANTIBODIES	K180 K181	Gliadin IgG EIA Gliadin IgA EIA	DE/CA64/00115860
19.	IMMUNOGLOBULIN E - TOTAL	K200	Total IgE EIA	DE/CA64/00115861
20.	THYROID STIMULATING HORMONE	K201	TSH EIA	DE/CA64/00115863
21.	LUTEINISING HORMONE	K202	LH EIA	DE/CA64/00115864
22.	FOLLICLE STIMULATING HORMONE	K203	FSH EIA	DE/CA64/00115865
23.	HUMAN GROWTH HORMONE	K204	GH EIA	DE/CA64/00115866
24.	HUMAN CHORIONIC GONADOTROPIN TOTAL	K205	hCG EIA	DE/CA64/00115867
25.	PROLACTIN	K206	Prolactin EIA	DE/CA64/00115868

The above-mentioned medical products are marked with the CE symbol.
Die oben genannten medizinischen Produkte sind mit dem CE-Zeichen gekennzeichnet.

Annex to the Certificate No.:

Anhang zum Zertifikat Nr.:

AR/IVD/XEMA LLC/01/2023

The following medical devices can be placed on the market in the Federal Republic of Germany, in the member states of the European Economic Community (EEC) and in the other contract states of the agreement about the European Economic Area.

Die folgenden Medizinprodukte in der Bundesrepublik Deutschland, in den Mitgliedsstaaten der Europäischen Wirtschaftsgemeinschaft (EG) und in den Vertragsstaaten der EG in den Verkehr gebracht werden dürfen.

#	Nomenclature term Nomenklaturbezeichnung	Catalog No. Katalog-Nr.	Name of device Produktbezeichnung	DMIDS Registration number Registriernummer
26.	PROGESTERONE	K207	Progesterone EIA	DE/CA64/00115869
27.	ESTRADIOL	K208	Estradiol EIA	DE/CA64/00115870
28.	TESTOSTERONE (WITH DEHYDRO AND FREE TESTOSTERONE)	K209	Testosterone EIA	DE/CA64/00115871
29.	CORTISOL	K210	Cortisol EIA	DE/CA64/00115872
30.	TRIIODOTHYRONINE	K211	T3 EIA	DE/CA64/00115873
31.	THYROXINE	K212	T4 EIA	DE/CA64/00115874
32.	FREE TRIIODOTHYRONINE	K213	ft3 EIA	DE/CA64/00115875
33.	FREE THYROXINE	K214	ft4 EIA	DE/CA64/00115876
34.	DEHYDRO-EPIANDROSTERONE SULPHATE (INCL. DHEA)	K215	DHEAS EIA	DE/CA64/00115877
35.	17 OH PROGESTERONE	K217	17-OH-progesterone EIA	DE/CA64/00115878
36.	ESTRIOL	K218	free Estriol EIA	DE/CA64/00115880
37.	TESTOSTERONE (WITH DEHYDRO AND FREE TESTOSTERONE)	K219	free Testosterone EIA	DE/CA64/00115881
38.	CANCER ANTIGEN 125	K222	CA 125 EIA	DE/CA64/00115882
39.	CANCER ANTIGEN 19-9	K223	CA 19-9 EIA	DE/CA64/00115883
40.	CARCINOEMBRYONIC ANTIGEN	K224	CEA EIA	DE/CA64/00115884
41.	ALPHAFETOPROTEIN	K225	AFP EIA	DE/CA64/00115885
42.	CANCER ANTIGEN 15-3	K226	CA 15-3 (M12) EIA	DE/CA64/00115886
43.	OTHER OTHER TUMOUR MARKERS	K232	Thyroglobulin EIA	DE/CA64/00115887
44.	β HUMAN CHORIONIC GONADOTROPIN (INCL. SUBUNIT)	K235	free β-HCG EIA	DE/CA64/00115888
45.	CYFRA 21-1	K236	CYFRA 21-1 EIA	DE/CA64/00115889
46.	SQUAMOUS CELL CARCINOMA ANTIGEN	K237	SCC (A) EIA	DE/CA64/00115890
47.	PREGNANCY ASSOCIATED PLASMA PROTEIN - A (DOWNS)	K238	PAPP-A EIA	DE/CA64/00115892
48.	OTHER OTHER TUMOUR MARKERS	K239	HE4 EIA	DE/CA64/00115893
49.	CANCER ANTIGEN 242	K243	CA242 EIA	DE/CA64/00115894
50.	OTHER PREGNANCY TESTING HORMONES	K245	AMH EIA	DE/CA64/00115896

The above-mentioned medical products are marked with the CE symbol.
Die oben genannten medizinischen Produkte sind mit dem CE-Zeichen gekennzeichnet.

Annex to the Certificate No.:

Anhang zum Zertifikat Nr.:

AR/IVD/XEMA LLC/01/2023

The following medical devices can be placed on the market in the Federal Republic of Germany, in the member states of the European Economic Community (EEC) and in the other contract states of the agreement about the European Economic Area.

Die folgenden Medizinprodukte in der Bundesrepublik Deutschland, in den Mitgliedsstaaten der Europäischen Wirtschaftsgemeinschaft (EG) und in den Vertragsstaaten der EG in den Verkehr gebracht werden dürfen.

#	Nomenclature term Nomenklaturbezeichnung	Catalog No. Katalog-Nr.	Name of device Produktbezeichnung	DMIDS Registration number Registriernummer
51.	HUMAN PLACENTAL LACTOGEN HPL	K246	Placental lactogen EIA	DE/CA64/00115897
52.	C-REACTIVE PROTEIN	K250	CRP EIA	DE/CA64/00115898
53.	C-PEPTIDE	K267C	C-peptide EIA	DE/CA64/00115900
54.	INSULIN	K267N	Insulin EIA	DE/CA64/00115901
55.	SEX HORMONE BINDING GLOBULIN	K268	SHBG EIA	DE/CA64/00115902
56.	TROPONIN (T + I)	K291	Troponin I EIA	DE/CA64/00115903
57.	LYME ANTIBODY IGG	K118G	Borelia burgdorferi IgG EIA	DE/CA64/00115904
58.	LYME ANTIBODY IGM	K118M	Borelia burgdorferi IgM EIA	DE/CA64/00115905
59.	EBV ANTIBODIES	K108V K108VM K108N	Epstein-Barr virus VCA IgG EIA Epstein-Barr virus VCA IgM EIA Epstein-Barr virus EBNA IgG EIA	DE/CA64/00115906

The above-mentioned medical products are marked with the CE symbol.
Die oben genannten medizinischen Produkte sind mit dem CE-Zeichen gekennzeichnet.

Represented in the EC by:

Polmed.de Beata Rozwadowska
Fichtenstr. 12A, 90763 Fürth, Germany
email: info@polmed.de
Tel: +49 911 93163967

SRN: DE-AR-000006947Date: **March 07, 2023**

Polmed.de



Instruction for use
A solid-phase enzyme immunoassay kit
for the quantitative determination of
autoantibodies to thyroglobulin
in human serum or plasma

aTG EIA

Catalogue number **REF K132**



For 96 determinations



In vitro diagnostic medical device




XEMA LLC
Akademika Yefremova St. 23
03179, Kyiv, Ukraine
tel.:+38 044 422-62-16
tel.:+38 044 294-69-78
E-mail: qa@xema.com.ua
www.xema.com.ua



Authorized Representative in EU:
Polmed.de Beata Rozwadowska
Fichtenstr. 12A, 90763 Fuerth, Germany
tel.:+ 49 911 931 639 67
E-mail: info@polmed.de
www.polmed.de

ASSAY PROCEDURE



CONTENT

1. INTENDED USE	2
2. GENERAL INFORMATION	2
3. TEST PRINCIPLE	3
4. KIT COMPONENTS	4
5. EQUIPMENT AND MATERIAL REQUIRED BUT NOT PROVIDED	5
6. WARNING AND PRECAUTIONS	5
7. SPECIMEN COLLECTION, TRANSPORTATION AND STORAGE OF SAMPLES	6
8. TRANSPORTATION AND STORAGE TERMS OF KIT, WASTE DISPOSAL	6
9. REAGENTS PREPARATION	7
10. ASSAY PROCEDURE	8
11. TEST VALIDITY	9
12. EXPECTED VALUES	9
13. PERFORMANCE CHARACTERISTICS	10
14. REFERENCES	10
SAMPLES IDENTIFICATION PLAN	12

Instruction for use
A solid-phase enzyme immunoassay kit
for the quantitative determination of
autoantibodies to thyroglobulin in human serum or plasma
aTG EIA

1. INTENDED USE

The aTG EIA kit is an enzyme immunoassay, intended for the quantitative determination of autoantibodies to thyroglobulin in human serum or plasma.

The field of application is clinical laboratory diagnostics.

2. GENERAL INFORMATION

Thyroglobulin (TG) is a well known target for autoantibodies occurring in thyroid autoimmunity (Graves' disease and Hashimoto's thyroiditis). Anti-TG antibodies mostly belong to the IgG class. Low to moderate levels of anti-TG antibodies can be found in sera of other autoimmune patients (eg systemic lupus erythematosus or Sjogren syndrome).

In some cases anti-TG positive sera may show negativity for other type of anti-thyroid antibodies – anti-TPO. Therefore, combined determination of both types of anti-thyroid antibodies (anti-TPO + anti-TG) provides most sensitive laboratory diagnostic tool for thyroid autoimmunity. Separately from autoimmunity, anti-TG antibodies may develop in patients suffering from thyroid cancer. High level of anti-TG in such patients may interfere with correct determination of serum thyroglobulin which serves as tumour marker for therapy control in this group of patients.

3. PRINCIPLE OF THE TEST

The determination of the anti-TG antibodies (aTG) is based on the indirect enzyme immunoassay principle. On the inner surface of the microplate wells are immobilized antigen Thyroglobulin. Second antibodies – murine monoclonal anti-IgG antibodies conjugated to the horseradish peroxidase is used as enzyme conjugate. The analysis procedure includes three stages of incubation:

- during the first stage specific to antigen anti-TG antibodies from the specimen are bound by antigens coated onto the microwell surface;
- during the second stage horseradish peroxidase-conjugated murine monoclonal antibodies bind to the antigen-antibody complexes, fixed in the formed at the previous stage complexes;
- during the third stage, the complexes formed due to the reaction with the chromogen 3,3',5,5'-tetramethylbenzidine are visualized.

After stopping the reaction with a stop solution, the intensity of the color of the microwells is measured. The optical density in the microwell is directly related to the quantity of the measured specific autoantibodies to thyroglobulin in test specimen.

The concentration is determined according to the calibration graph of the dependence of the optical density on the content of anti-TG antibodies in the calibration samples.

4. KIT COMPONENTS

Code of component	Symbol	Name	Volume	Qty, pcs.	Description
P132Z	SORB MTP	Microplate	-	1	96-well polystyrene strip microplate coated with antigen Thyroglobulin; ready to use
C132Z	CAL 1	Calibrator C1	1.1 mL	1	Solution based on phosphate buffer (pH 7.2-7.4), free of anti-TG antibodies, with preservative, ready to use (colourless liquid)
C132Z	CAL 2-5	Calibrators	1.1 mL	4	Solutions based on phosphate buffer (pH 7.2-7.4), containing 100; 300; 1000 and 3000 IU/mL of anti-TG antibodies, with preservative, ready to use (blue liquids)
Q132Z	CONTROL	Control Serum	1.1 mL	1	Solution based on human serum, containing of known anti-TG antibodies content, with preservative, ready to use (colourless liquid)
T132Z	CONJ HRP	Conjugate Solution	14 mL	1	Solution of murine monoclonal antibodies to IgG conjugated to the horseradish peroxidase; ready to use (magenta liquid)
S011Z3	DIL	EIA Buffer	50 mL	1	Buffer solution with detergent and preservative, ready to use (blue liquid)
R055Z	SUBS TMB	Substrate Solution	14 mL	1	Tetramethylbenzidine (TMB) substrate solution; ready to use (colourless liquid)
S008Z	BUF WASH 26X	26x Concentrate Washing Solution	22 mL	2	Buffer solution with detergent, 26x concentrate (colourless liquid)
R050Z	STOP	Stop Solution	14 mL	1	5.0% solution of sulphuric acid; ready to use (colourless liquid)
The kit also includes instruction for use, quality control data sheet and plate sealing tape (3 pcs.)					

5. EQUIPMENT AND MATERIAL REQUIRED BUT NOT PROVIDED

- microplate photometer with 450 nm or 450\620-680 nm wavelength;
- dry thermostat for $+37^{\circ}\text{C}\pm 1^{\circ}\text{C}$;
- automatic plate washer (optional);
- micropipettes with variable volume, range volume 5-1000 μL ;
- graduated cylinder of 1000 mL capacity;
- distilled or deionized water;
- timer;
- vortex mixer;
- disposable gloves;
- absorbent paper.

6. WARNING AND PRECAUTIONS

In order to prevent incorrect results, strictly follow the recommended order and duration of the analysis procedure.

6.1. The kit is for *in vitro* diagnostic use only. For professional laboratory use.

6.2. Follow the rules mentioned below during the kit using:

- do not use kit beyond expire date;
- do not use the kit if its packaging is damaged;
- in order to avoid contamination, use new tips to pipette samples and reagents;
- use only verified equipment;
- close each vial with its own cap, after using the reagent;
- do not use components of other kits or reagents of other manufacturers;
- do not let wells dry after completing the rinsing step; immediately proceed to the next stage;
- avoid bubbles when adding reagents.

ATTENTION! The TMB substrate solution is light sensitive. Avoid prolonged exposure of the component to light.

6.3. Some kit components, such as stop solution, substrate solution, and washing solution, may cause toxic or irritant effects. If they get on the skin or mucosa, the affected area should be washed with plenty of running water.

6.4. All human products, including patient samples, should be considered potentially infectious. Handling and disposal should be in accordance with the procedures defined by an appropriate national biohazard safety guidelines or regulations.

6.5. The Calibrators and Control Serum included in the kit are negative for antibodies to HIV 1,2, hepatitis C virus and HBsAg, but the reagents should be considered as potentially infectious material and handled carefully.

6.6. Specimens must not contain any azide compounds, as they inhibit activity of peroxidase.

6.7. Wear protective gloves, protective clothing, eye protection, face protection.

6.8. Do not smoke, eat, drink or apply cosmetics in areas where specimens or kit reagents are handled.

6.9. Safety Data Sheet for this product is available upon request directly from XEMA LLC.

6.10. Serious incidents related to the kit must be reported to the manufacturer, Authorized Representative, and to the Competent Authority of the EU member state(s) where the incident has occurred.

7. SPECIMEN COLLECTION, TRANSPORTATION AND STORAGE OF SAMPLES

7.1. Blood sampling should be carried out from the cubital vein with a disposable needle using a vacuum blood sampling system. Serum or plasma specimens should be clearly labeled and identified. Serum must be separated from the clot as early as possible to avoid hemolysis of red blood cells. If there are any visible particles in the sample, they should be removed by centrifugation at 3000-5000 rpm for 20 minutes at room temperature or by filtration.

Don't use samples with high lipidemia, hemolysis as they may give false test results.

7.2. Specimen should be stored at +2...+8°C up to 3 days. Specimen held for a longer time, should be placed in a freezer at -15°C or below; do not refreeze/thaw samples.

7.3. For the transportation of samples, it is recommended to use triple packaging. The primary package is the labeled tube containing the sample. Secondary packaging is a polyethylene bag that is hermetically closed with a zip-lock. The outer packaging is a heat-insulating container, while the secondary packaging is placed in the outer packaging for transportation in the center of the thermal container. Frozen refrigerants are placed on the bottom, along the side walls of the thermal container, and cover the samples with them.

8. TRANSPORTATION AND STORAGE TERMS OF KIT, WASTE DISPOSAL

Information about the singularity storage conditions, transportation of the kit, and disposal of waste should be taken into account by all persons who participate in these processes.

8.1. Transportation

The aTG EIA kit should be transported in the manufacturer's packaging at +2...+8°C. Single transportation at the temperature up to 25°C for 5 days is acceptable.

8.2. Storage

The aTG EIA kit should be stored in the manufacturer's packaging at +2...+8°C. Do not freeze.

The kit contains reagents sufficient for 96 determinations including Calibrators and Control Serum.

Once opened test-kit is stable for 2 months when stored properly as intended by manufacturer at 2-8°C.

In case of partial use of the kit, the components should be stored in the following way:

- strips that remain unused must be carefully sealed with the plate sealing tape and stored at +2...+8°C within 2 months;
- EIA Buffer, Substrate Solution, Stop Solution, and Washing Solution concentrate after opening the vial, can be stored tightly closed at +2...+8°C until the kit's shelf life;
- Conjugate Solution, Calibrators and Control Serum after opening the vial, can be stored tightly closed at +2...+8°C within 2 months
- diluted Washing Solution can be stored at room temperature (+18...+25°C) for up to 5 days or at +2...+8°C for up to 14 days.

Kits that were stored in violation of the storage condition cannot be used.

8.3. Disposal

Expired kit components, used reagents and materials, as well as residual samples must be inactivated and disposed of in accordance with legal requirements.

9. REAGENTS PREPARATION

9.1. All reagents (including microstrips) and test samples should be allowed to reach room temperature (+18...+25 °C) for at least 30 minutes before use.

9.2. Microplate preparation

Open the package with the microplate and install the required number of strips into the frame. Unused strips must be sealed with plate sealing tape to prevent moisture from affecting the plate's holes and placed back in the bag.

9.3. Washing solution preparation

Add the contents of the 22 mL washing solution concentrate vial to 550 mL of distilled or deionized water and mix thoroughly. In case of partial use of the kit, take the necessary amount of washing solution concentrate and dilute it 26 times with distilled or deionized water.

The spending of the components in case of partial use of the kit is given in the table:

Quantity of strips	1	2	3	4	5	6	7	8	9	10	11	12
Volume of the washing solution concentrate, mL	1.8	3.6	5.4	7.2	9	10.8	12.6	14.4	16.2	18	19.8	22
Volume of water, mL	45	90	135	180	225	270	315	360	405	450	495	550

9.4. Samples preparation

Dilute samples using EIA buffer 101 fold (for example, add to the vial 5 µL of the test sample + 500 µL EIA buffer).

If suggested analyte concentration in the sample exceeds the 3000 IU/mL, additionally dilute this sample accordingly, using EIA buffer. Use of other buffers or reagents for sample dilution may lead to incorrect measurement.

NOTE: in order to obtain reliable results, we recommend to use several successive dilutions of biological fluids.

Do not dilute Control Serum and Calibrators!

10. ASSAY PROCEDURE

- Put the desired number of strips into the frame based on the number of test samples in 2 replicates and 12 wells for Calibrators and Control Serum (2 wells for each Calibrator (CAL 1-5) and 2 wells for Control Serum (Q)).
- Dilute the test samples as described in 9.4.
- Dispense **100 µL of Calibrators and Control Serum as well as 100 µL of diluted test serum/plasma samples** (SAMP) to the wells of the microplate according to the scheme below. The introduction of Calibrators, Control Serum and test samples should be carried out within 5 minutes to ensure equal incubation time for the first and last samples.

NOTE: during performing several independent series of tests, Calibrators, and Control Serum should be used each time.

Scheme of introduction of samples

	1	2	3	4	5	6	7	8	9	10	11	12
A	CAL1	CAL1	SAMP3	SAMP3	SAMP11	SAMP11						
B	CAL2	CAL2	SAMP4	SAMP4	SAMP12	SAMP12						
C	CAL3	CAL3	SAMP5	SAMP5	SAMP13	SAMP13						
D	CAL4	CAL4	SAMP6	SAMP6	SAMP14	SAMP14						
E	CAL5	CAL5	SAMP7	SAMP7	SAMP15	SAMP15						
F	Q	Q	SAMP8	SAMP8								
G	SAMP1	SAMP1	SAMP9	SAMP9								
H	SAMP2	SAMP2	SAMP10	SAMP10								

- 10.4 Carefully mix the contents of the microplate in a circular motion on a horizontal surface, cover strips with a plate sealing tape and incubate for **30 minutes at +37°C**.
- 10.5 At the end of the incubation period, remove and discard the plate cover. Aspirate and wash each well 3 times using an automatic washer or an 8-channel dispenser. For each washing, add 300 μL of Washing Solution (see 9.3) to all wells, then remove the liquid by aspiration or decantation. The residual volume of the Washing Solution after each aspiration or decantation should be no more than 5 μL . After washing, carefully remove the remaining liquid from the wells on the absorbent paper. For the automatic washer/analyzer, the Washing Solution volume can be increased to 350 μL .
- 10.6 Add **100 μL of Conjugate Solution** to all wells.
- 10.7 Cover strips with a plate sealing tape and incubate for **30 minutes at +37°C**.
- 10.8 At the end of the incubation period, aspirate and wash each well 5 times as described in 10.5.
- 10.9 Add **100 μL of Substrate Solution** to all wells. The introduction of the Substrate Solution into the wells must be carried out within 2-3 minutes. Incubate the microplate in the dark **at room temperature (+18...+25°C) for 15 minutes**.
- 10.10 Add **100 μL of Stop Solution** to all wells in the same order as the Substrate Solution. After adding the Stop Solution, the contents of the wells turn yellow.
- 10.11 Read the optical density (OD) of the wells at 450nm and reference light filters 620–680 nm using a microplate photometer within 5 minutes of adding the stop solution. Set photometer blank on CAL1.
- 10.12 Plot a calibration curve in linear coordinates: (x) is the concentration of aTG IU/mL in the calibrators, (y) – OD versus aTG concentration (OD 450 nm / 620–680 nm). Manual or computerized data reduction is applicable at this stage. Point-by-point or linear data reduction is recommended due to non-linear shape of curve.
- 10.13 Determine the corresponding concentration of aTG in tested samples from the calibration curve. In the case of preliminary dilution of the test sample (see 9.4), the obtained result should be multiplied by the dilution factor.

11. TEST VALIDITY

The test run shall be considered valid if the OD of CAL1 is above 0.15, and the values of the Control Serum fall into the required range (see Quality control Data Sheet).

12. EXPECTED VALUES

Therapeutical consequences should not be based on results of IVD methods alone – all available clinical and laboratory findings should be used by a physician to elaborate therapeutically measures. Each laboratory should establish its own normal range for aTG. Based on data obtained by XEMA, the following normal range is recommended (see below).

NOTE: values of aTG concentrations in the tested samples that are below the LoD (5.0 IU/mL) and also exceed the value of the upper calibrator (3000 IU/mL) should be provided in the following form: «the aTG concentration of tested sample X is «lower than 5.0 IU/mL» or «higher than 3000 IU/mL».

Sex, age	Units, IU/mL	
	Lower limit	Upper limit
Males	-	100
Females	-	100
Females >50 yrs	-	150

13. PERFORMANCE CHARACTERISTICS

13.1. Analytical performance characteristics

13.1.1 Precision of Measurement

Repeatability (Intra assay repeatability) was determined by evaluation the coefficient of variation (CV) for 2 different samples during 1 day in 24 replicates on one series of ELISA kit.

Sample	Concentration, IU/mL	CV, %
1	1256.9	2.46
2	110.7	5.39

Reproducibility (Inter assay reproducibility) was determined by evaluating the coefficients of variation for 2 samples during 5 days in 8-replicate determinations.

Sample	Concentration, IU/mL	CV, %
1	1264.5	4.33
2	107.9	6.43

Reproducibility between lots was investigated by testing samples for one day on three lots. Each sample was run in 8 replicates.

Sample	Concentration1, IU/mL	Concentration2, IU/mL	Concentration3, IU/mL	CV, %
121	1270.5	1262.8	1276.6	0.54
433	109.4	114.5	118.5	4.00

13.1.2 Trueness

The trueness of measurement is the degree of closeness of the average value obtained from a large number of measurement results to the true value. The bias of the measurement result (bias of measurements) is the difference between the mathematical expectation of the measurement result and the true value of the measurand. The bias was calculated for each sample and it was determined that it corresponds to the specified limits of $\pm 10\%$.

13.1.3 Linearity

Linearity was determined using sera samples with known aTG concentration (low and high) and mixing them with each other and buffer solution in different proportions. According to the measurements, linear range of kit is 100-3000 IU/mL $\pm 10\%$.

13.1.4 Analytical sensitivity

Limit of detection (LoD) – the lowest aTG concentration in the serum or plasma sample that is detected by the aTG EIA kit is no lower than 5 IU/mL.

Limit of quantification (LoQ) – the lowest concentration of the analyte in the sample that is determined quantitatively with the declared trueness for aTG EIA kit is 100 IU/mL.

13.1.5 Analytical specificity

For the analysis result is not affected by the presence in the sample of bilirubin in a concentration of up to 0.21 mg/mL and hemoglobin in a concentration of up to 10 mg/mL.

14. REFERENCES

1. U Feldt-Rasmussen – Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor. Clin. Chem., Jan 1996; 42: 160 – 163.
2. PW Ladenson – Optimal laboratory testing for diagnosis and monitoring of thyroid nodules, goiter, and thyroid cancer. Clin. Chem., Jan 1996; 42: 183 – 187.
3. Anthony P. Weetman – Graves' Disease. N. Engl. J. Med., Oct 2000; 343: 1236 – 1248.
4. Buchanan W., Alexander W., Crooks J., Koutras D., Wayne E., Anderson J.R., Goudie R. – Association of thyrotoxicosis and autoimmune thyroiditis. Brit.Med. J., 1961, 1:843.
4. Наказ МОЗ України №325 від 08.06.2015 «Про затвердження Державних санітарно-протиепідемічних правил і норм щодо поведження з медичними відходами».
5. Постанова КМУ від 02 жовтня 2013р. №754 «Про затвердження технічного регламенту щодо медичних виробів для діагностики in vitro».
6. НПАОП 85.14-1.09-81. Правила облаштування, техніки безпеки, виробничої санітарії, протиепідемічного режиму і особистої гігієни при роботі в лабораторіях (відділеннях, відділах) санітарноепідеміологічних установ системи Міністерства охорони здоров`я СРСР (НАОП 9.1.50-1.09-81)

SAMPLES IDENTIFICATION PLAN













	1	2	3	4	5	6	7	8	9	10	11	12
A												
B												
C												
D												
E												
F												
G												
H												

LOT _____ DATE _____

SAMPLES IDENTIFICATION PLAN

	1	2	3	4	5	6	7	8	9	10	11	12
A												
B												
C												
D												
E												
F												
G												
H												

LOT _____ DATE _____

	Manufacturer
	<i>In vitro</i> diagnostic medical device
	Catalogue number
 YYYY-MM	Use-by date
	Batch code
	Temperature limit
	Contains sufficient for <n> tests
	Caution
	Consult instructions for use
	Conformity Marking with technical regulations in Ukraine
	Authorized representative in the European Community/European Union
	CE Conformity Marking

**For any issues related to operation of the kit and technical support,
please contact by telefon number**

+38 044 294-69-78

or write to:

qa@xema.com.ua



XEMA LLC
Akademika Yefremova St. 23
03179, Kyiv, Ukraine
tel.:+38 044 422-62-16
tel.:+38 044 294-69-78
E-mail: qa@xema.com.ua
www.xema.com.ua



Instruction for use
A solid-phase enzyme immunoassay kit
for the quantitative determination of
CA 125 in human serum or plasma

CA 125 EIA

On the website www.xema.com.ua is available a calculator for calculating the risk of ovarian cancer based on the results of the testing CA 125 and HE4 antigens using EIA kits manufactured by our company.

Catalogue number **REF** **K222**



For 96 determinations



In vitro diagnostic medical device



XEMA LLC
Akademika Yefremova St. 23
03179, Kyiv, Ukraine
tel.:+38 050 422-62-16
tel.:+38 044 294-69-78
E-mail: qa@xema.com.ua
www.xema.in.ua



Authorized Representative in EU:
Polmed.de Beata Rozwadowska
Fichtenstr. 12A, 90763 Fuerth, Germany
tel.:+ 49 911 931 639 67
E-mail: info@polmed.de
www.polmed.de

ASSAY PROCEDURE

Dispensing of calibrators, control serum and test samples

test samples

CAL

CONTROL

SORB MTP

50 μ L

Conjugate Solution

CONJ HRP

50 μ L

Incubation 1

+37 $^{\circ}$ C

60'

Washing 5 times

Washing 5 times

OD measuring, calculation of results

450 / 620-680 nm

Stop Solution

STOP

100 μ L

Incubation 2

+18-25 $^{\circ}$ C

15'

Substrate Solution

SUBS TMB

100 μ L

CONTENT

1. INTENDED USE	2
2. GENERAL INFORMATION	2
3. TEST PRINCIPLE	3
4. KIT COMPONENTS	4
5. EQUIPMENT AND MATERIAL REQUIRED BUT NOT PROVIDED	5
6. WARNING AND PRECAUTIONS	5
7. SPECIMEN COLLECTION, TRANSPORTATION AND STORAGE OF SAMPLES	6
8. TRANSPORTATION AND STORAGE TERMS OF KIT, WASTE DISPOSAL	6
9. REAGENTS PREPARATION	7
10. ASSAY PROCEDURE	7
11. TEST VALIDITY	9
12. EXPECTED VALUES	9
13. PERFORMANCE CHARACTERISTICS	9
14. REFERENCES	10
SAMPLES IDENTIFICATION PLAN	11

Instruction for use
A solid-phase enzyme immunoassay kit
for the quantitative determination of
CA 125 in human serum or plasma
CA 125 EIA

1. INTENDED USE

The CA 125 EIA kit is an enzyme immunoassay, intended for the quantitative determination of CA 125 in human serum or plasma.

Quantitative determination of CA 125 in serum (plasma) is used to monitor patients with ovarian adenocarcinomas.

The field of application is clinical laboratory diagnostics.

2. GENERAL INFORMATION

CA 125 is an antigen (an epitope) associated with ovarian carcinoma and some other tumors. The CA125 epitope is found on a heterogeneous group of glycoproteins with a high molecular weight (MW 200.000 to over 1.000.000). In a high percentage of cases, CA 125 is increased in adenocarcinomas ovaries, with the exception of mucinous and granulosa cell histology forms. In addition, CA125 is detectable in some fetal tissues and in adult tissues in the epithelium of the fallopian tubes, apocrine sweat glands, breast glands, endometrium and endocervix. Elevated serum concentrations of CA125 are found in most patients with epithelial ovarian cancer, including those with stage 1 disease. CA125 determination is useful for therapy control and follow-up of ovarian cancer patients treated by any type of therapy. However, the CA125 values obtained should always be interpreted in the context of the results obtained by other clinical procedures.

Internal data obtained by XEMA suggest that serial determination of CA125 may be helpful for diagnosis of adenocarcinoma development in fibrotic lung tissue in patients with interstitial lung diseases. In a present test system, monoclonal antibodies X306 (epitope group A) is used to capture the antigen, and monoclonal antibodies X52 (epitope group B) are used as a tracer. The epitope specificity of both antibodies were confirmed by an independent expert group (TD1 workshop 2000, International Society of Oncodevelopmental Biology and Medicine).

Determination of CA125 is not suitable for early diagnosis of malignancies because elevated CA125 values may also be found in patients with uterine carcinoma, hepatoma and pancreatic adenocarcinoma as well as in non-malignant conditions such as liver cirrhosis, interstitial lung diseases.

WARNING! This kit is intended for use only with serum or plasma human blood. When analyzing other types of samples – for example, ascitic fluid, pleural effusions or culture supernatants may be obtained false results.

3. PRINCIPLE OF THE TEST

The determination of the CA 125 is based on the two-site sandwich enzyme immunoassay principle. On the inner surface of the microplate wells are immobilized specific murine monoclonal antibodies to human CA 125. Second antibodies – murine monoclonal antibodies to human CA125 conjugated to the horseradish peroxidase is used as enzyme conjugate. The analysis procedure includes two stages of incubation:

- during the first stage CA 125 from the specimen is captured by the antibodies coated onto the microwell surface, as well as horseradish peroxidase-conjugated monoclonal antibodies bind to free epitopes of immobilized CA 125;

- during the second stage, the complexes formed due to the reaction with the chromogen 3,3',5,5'-tetramethylbenzidine are visualized.

After stopping the reaction with a stop solution, the intensity of the color of the microwells is measured. The optical density in the microwell is directly related to the quantity of the measured CA 125 in the serum specimen (plasma). The concentration is determined according to the calibration graph of the dependence of the optical density on the content of CA 125 in the calibration samples.

4. KIT COMPONENTS

Code of component	Symbol	Name	Volume	Qty, pcs.	Description
P222Z	SORB MTP	Microplate	-	1	96-well polystyrene strip microplate coated with murine monoclonal antibodies to human CA125; ready to use
C222Z	CAL 1	Calibrator C1	6 mL	1	Solution based on tris buffer (pH 7.2-7.4), free of human CA125, with preservative, ready to use (yellow liquid)
C222Z	CAL 2-6	Calibrators	0.6 mL	5	Solutions based on tris buffer (pH 7.2-7.4), containing 25; 50; 100; 200 and 400 U/mL of human CA 125, ready to use (red liquids)
Q222Z	CONTROL	Control Serum	0.6 mL	1	Solution based on human serum, containing of known human CA 125 content, with preservative, ready to use (colourless liquid)
T222Z	CONJ HRP	Conjugate Solution	7 mL	1	Solution of murine monoclonal antibodies to CA 125 conjugated to the horseradish peroxidase; ready to use (red liquid)
R055Z	SUBS TMB	Substrate Solution	12 mL	1	Tetramethylbenzidine (TMB) substrate solution; ready to use (colourless liquid)
S008Z	BUF WASH 26X	26x Concentrate Washing Solution	22 mL	1	Buffer solution with detergent, 26x concentrate (colourless liquid)
R050Z	STOP	Stop Solution	12 mL	1	5.0% solution of sulphuric acid; ready to use (colourless liquid)

The kit also includes instruction for use, quality control data sheet and plate sealing tape (1 pcs.)

5. EQUIPMENT AND MATERIAL REQUIRED BUT NOT PROVIDED

- microplate photometer with 450 nm wavelength or 450\620-680 nm;
- dry thermostat for 37°C±1°C;
- automatic plate washer (optional);
- micropipettes with variable volume, range volume 5-1000 µL;
- graduated cylinder of 1000 mL capacity;
- distilled or deionized water;
- timer;
- vortex mixer;
- disposable gloves;
- absorbent paper.

6. WARNING AND PRECAUTIONS

In order to prevent incorrect results, strictly follow the recommended order and duration of the analysis procedure.

6.1. The kit is for *in vitro* diagnostic use only. For professional laboratory use.

6.2. Follow the rules mentioned below during the kit using:

- do not use kit beyond expire date;
- do not use the kit if its packaging is damaged;
- in order to avoid contamination, use new tips to pipette samples and reagents;
- use only verified equipment;
- close each vial with its own cap, after using the reagent;
- do not use components of other kits or reagents of other manufacturers;
- do not let wells dry after completing the rinsing step; immediately proceed to the next stage;
- avoid bubbles when adding reagents.

ATTENTION! The TMB substrate solution is light sensitive. Avoid prolonged exposure of the component to light.

6.3. Some kit components, such as stop solution, substrate solution, and washing solution, may cause toxic or irritant effects. If they get on the skin or mucosa, the affected area should be washed with plenty of running water.

6.4. All human products, including patient samples, should be considered potentially infectious. Handling and disposal should be in accordance with the procedures defined by an appropriate national biohazard safety guidelines or regulations.

6.5. The Calibrators and Control Serum included in the kit are negative for antibodies to HIV 1,2, hepatitis C virus and HBsAg, but the reagents should be considered as potentially infectious material and handled carefully.

6.6. Specimens must not contain any azide compounds, as they inhibit activity of peroxidase.

6.7. Wear protective gloves, protective clothing, eye protection, face protection.

6.8. Do not smoke, eat, drink or apply cosmetics in areas where specimens or kit reagents are handled.

6.9. Safety Data Sheet for this product is available upon request directly from XEMA LLC.

6.10. Serious incidents related to the kit must be reported to the manufacturer, Authorized Representative, and to the Competent Authority of the EU member state(s) where the incident has occurred.

7. SPECIMEN COLLECTION, TRANSPORTATION AND STORAGE OF SAMPLES

7.1. Blood sampling should be carried out from the cubital vein with a disposable needle using a vacuum blood sampling system. Serum or plasma specimens should be clearly labeled and identified. Serum must be separated from the clot as early as possible to avoid hemolysis of red blood cells. If there are any visible particles in the sample, they should be removed by centrifugation at 3000-5000 rpm for 20 minutes at room temperature or by filtration.

Don't use samples with high lipidemia, hemolysis as they may give false test results.

7.2. Specimen should be stored at +2...+8°C up to 3 days. Specimen held for a longer time, should be placed in a freezer at -15°C or below, do not refreeze/thaw samples.

7.3. For the transportation of samples, it is recommended to use triple packaging. The primary package is the labeled tube containing the sample. Secondary packaging is a polyethylene bag that is hermetically closed with a zip-lock. The outer packaging is a heat-insulating container, while the secondary packaging is placed in the outer packaging for transportation in the center of the thermal container. Frozen refrigerants are placed on the bottom, along the side walls of the thermal container, and cover the samples with them.

8. TRANSPORTATION AND STORAGE TERMS OF KIT, WASTE DISPOSAL

Information about the singularity storage conditions, transportation of the kit, and disposal of waste should be taken into account by all persons who participate in these processes.

8.1. Transportation

The CA 125 EIA kit should be transported in the manufacturer's packaging at +2...+8°C. Single transportation at the temperature up to 25°C for 5 days is acceptable.

8.2. Storage

The CA 125 EIA kit should be stored in the manufacturer's packaging at +2...+8°C. Do not freeze.

The kit contains reagents sufficient for 96 determinations including Calibrators and Control Serum.

Once opened test-kit is stable for 2 months when stored properly as intended by manufacturer at 2-8°C.

In case of partial use of the kit, the components should be stored in the following way:

- the remaining strips should be immediately resealed in the bag along with the silica gel, closed with the zip-lock, and stored at +2...+8°C within 2 months;
- Substrate Solution, Stop Solution, and Washing Solution concentrate after opening the vial, can be stored tightly closed at +2...+8°C until the kit's shelf life;
- Conjugate Solution, Calibrators and Control Serum after opening the vial, can be stored tightly closed at +2...+8°C within 2 months;

NOTE: Single freezing of Calibrators and Control Serum in aliquots is allowed.

- diluted Washing Solution can be stored at room temperature (+18...+25°C) for up to 5 days or at +2...+8°C for up to 14 days.

Kits that were stored in violation of the storage condition cannot be used.

8.3. Disposal

Expired kit components, used reagents and materials, as well as residual samples must be inactivated and disposed of in accordance with legal requirements.

9. REAGENTS PREPARATION

9.1. All reagents (including microstrips) and test samples should be allowed to reach room temperature (+18...+25 °C) for at least 30 minutes before use.

9.2. Microplate preparation

Open the package with the microplate and install the required number of strips into the frame. The remaining strips should be immediately resealed in the bag along with the silica gel and closed with the zip-lock to prevent moisture from affecting the plate's strips.

9.3. Washing Solution preparation

Add the contents of the 22 mL Washing Solution concentrate vial to 550 mL of distilled or deionized water and mix thoroughly. In case of partial use of the kit, take the necessary amount of Washing Solution concentrate and dilute it 26 times with distilled or deionized water.

The spending of the components in case of partial use of the kit is given in the table:

Quantity of strips	1	2	3	4	5	6	7	8	9	10	11	12
Volume of the Washing Solution concentrate, mL	1.8	3.6	5.4	7.2	9	10.8	12.6	14.4	16.2	18	19.8	22
Volume of water, mL	45	90	135	180	225	270	315	360	405	450	495	550

9.4. Samples preparation

If suggested analyte concentration in the sample exceeds the 400 U/mL, additionally dilute this sample accordingly, using (Calibrator C1). Use of other buffers or reagents for sample dilution may lead to incorrect measurement.

NOTE: in order to obtain reliable results, we recommend to use several successive dilutions of the blood serum (plasma) sample.

10. ASSAY PROCEDURE

- 10.1 Put the desired number of strips into the frame based on the number of test samples in 2 replicates and 14 wells for Calibrators and Control Serum (2 wells for each Calibrator (CAL 1-6) and 2 wells for Control Serum (Q)).
- 10.2 If necessary, dilute the test samples as described in 9.4.
- 10.3 Dispense **50 µL of Calibrators and Control Serum as well as 50 µL of test serum/plasma samples** (SAMP) to the wells of the microplate according to the scheme below. The introduction of Calibrators, Control Serum and test samples should be carried out within 5 minutes to ensure equal incubation time for the first and last samples.

NOTE: during performing several independent series of tests, Calibrators, and Control Serum should be used each time.

Scheme of introduction of samples

	1	2	3	4	5	6	7	8	9	10	11	12
A	CAL1	CAL1	SAMP2	SAMP2	SAMP10	SAMP10						
B	CAL2	CAL2	SAMP3	SAMP3	SAMP11	SAMP11						
C	CAL3	CAL3	SAMP4	SAMP4	SAMP12	SAMP12						
D	CAL4	CAL4	SAMP5	SAMP5								
E	CAL5	CAL5	SAMP6	SAMP6								
F	CAL6	CAL6	SAMP7	SAMP7								
G	Q	Q	SAMP8	SAMP8								
H	SAMP1	SAMP1	SAMP9	SAMP9								

- 10.4 Add **50 µL of Conjugate Solution** to all wells.
- 10.5 Carefully mix the contents of the microplate in a circular motion on a horizontal surface, cover strips with a plate sealing tape and incubate for **60 minutes at +37°C**.
- 10.6 At the end of the incubation period, remove and discard the plate cover. Aspirate and wash each well 5 times using an automatic washer or an 8-channel dispenser. For each washing, add 300 µL of Washing Solution (see 9.3) to all wells, then remove the liquid by aspiration or decantation. The residual volume of the Washing Solution after each aspiration or decantation should be no more than 5µL. After washing, carefully remove the remaining liquid from the wells on the absorbent paper. For the automatic washer/analyzer, the wash solution volume can be increased to 350 µL.
- 10.7 Add **100 µL of Substrate Solution** to all wells. The introduction of the Substrate Solution into the wells must be carried out within 2-3 minutes. Incubate the microplate in the dark **at room temperature (+18...+25°C) for 15 minutes**.
- 10.8 Add **100 µL of Stop Solution** to all wells in the same order as the Substrate Solution. After adding the Stop Solution, the contents of the wells turn yellow.
- 10.9 Read the optical density (OD) of the wells at 450nm and reference light filters 620–680 nm using a microplate photometer within 5 minutes of adding the Stop Solution. Set photometer blank on CAL1.
- 10.10 Plot a calibration curve in linear coordinates: (x) is the CA 125 concentration in the calibrators U/mL, (y) – OD versus CA 125 concentration (OD 450 nm / 620–680 nm). Manual or computerized data reduction is applicable at this stage. Point-by-point or linear data reduction is recommended due to non-linear shape of curve.
- 10.11 Determine the corresponding concentration of CA 125 in tested samples from the calibration curve. In the case of preliminary dilution of the test sample (see 9.4), the obtained result should be multiplied by the dilution factor.

11. TEST VALIDITY

The test run shall be considered valid if the OD of CAL1 is above 0.15, and the values of the Control Serum fall into the required range (see Quality control Data Sheet).

12. EXPECTED VALUES

Therapeutical consequences should not be based on the results of IVD methods alone – all available clinical and laboratory findings should be used by a physician to elaborate therapeutically measures. Each laboratory should establish its own normal range for CA 125. Based on data obtained by XEMA, the following normal range is recommended (see below).

NOTE: values of CA 125 concentrations in the tested samples that are below the LoD (0.25 U/mL) and also exceed the value of the upper Calibrator (400 U/mL) should be provided in the following form : «the CA 125 concentration of tested sample X is «lower than 0.25 U/mL» or «higher than 400 U/mL».

Sex, age	Одиниці, U/mL	
	Lower limit	Upper limit
Males	-	35
Females	-	35
Pregnancy week		
1st trimester	-	60
2nd trimester	-	150
3rd trimester	-	200
Lactation	-	80

13. PERFORMANCE CHARACTERISTICS

13.1. Analytical performance characteristics

13.1.1 Precision of Measurement

Repeatability (Intra assay repeatability) was determined by evaluation the coefficient of variation (CV) for 2 different samples during 1 day in 24 replicates on one series of ELISA kit.

Sample	Concentration, U/mL	CV, %
1	57.4	7.83
2	259	1.67

Reproducibility (Inter assay reproducibility) was determined by evaluating the coefficients of variation for 2 samples during 5 days in 8-replicate determinations.

Sample	Concentration, U/mL	CV, %
1	56.34	1.75
2	258.47	5.63

Reproducibility between lots was investigated by testing samples for one day on three lots. Each sample was run in 8 replicates.

Sample	Concentration1, U/mL	Concentration2, U/mL	CV, %
1	56.6	57.89	1.59
2	259.4	261.75	0.64

13.1.2 Trueness

The trueness of measurement is the degree of closeness of the average value obtained from a large number of measurement results to the true value. The bias of the measurement result (bias of measurements) is the difference between the mathematical expectation of the measurement result and the true value of the measurand. The bias was calculated for each sample and it was determined whether it corresponds to the specified limits of $\pm 10\%$.

13.1.3 Linearity

Linearity was determined using sera samples with known CA 125 concentration (low and high) and mixing them with each other and buffer solution in different proportions. According to the measurements, linear range of kit is 25–400 U/mL $\pm 10\%$.

13.1.4 Analytical sensitivity

Limit of detection (LoD) – the lowest CA 125 concentration in the serum or plasma sample that is detected by the CA 125 EIA kit is no lower than 0.25 U/mL.

Limit of quantification (LoQ) – the lowest concentration of the analyte in the sample that is determined quantitatively with the declared trueness for CA 125 EIA kit is 25 U/mL.

13.1.5 Hook Effect

Hook effect is absent for all samples up to reasonably foreseen concentrations 400 U/mL.

13.1.6 Analytical specificity

For the analysis result is not affected by the presence in the sample of bilirubin in a concentration of up to 0.21 mg/mL and hemoglobin in a concentration of up to 10 mg/mL.

The cross-reactivity of CA 125 with other analytes is shown in the table:

Analyte	Cross-reactivity, %
CEA	< 0.1
CA 19-9	< 0.1
CA 15-3	< 0.1













14. REFERENCES

1. Engall, E., Methods in Enzymology, Volume 70, Van Vunakis, H. and Langone, J. J. (eds.), Academic Press, New York, 419- 492. (1980).
2. Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. Ca125 in gynecological pathology a review. Eur J Obstet Gynecol 1993; 49:115-124
3. Saksela F. Prognostic markers in epithelial ovarian cancer. Intl J Gynecol Pathol 1993; 12:156-161
4. Farghaly SA. Tumor markers in gynecologic cancer. Gynecol & Obstet Invest 1992; 34:65-72
5. Welander CE. What do CA 125 and other antigens tell us about ovarian cancer biology. Acta Obstet Gynecol Scand Sup 1992; 155:85-93
6. Наказ МОЗ України №325 від 08.06.2015 «Про затвердження Державних санітарно-протиепідемічних правил і норм щодо поводження з медичними відходами».
7. Постанова КМУ від 02 жовтня 2013р. №754 «Про затвердження технічного регламенту щодо медичних виробів для діагностики in vitro».
8. НПАОП 85.14-1.09-81. Правила облаштування, техніки безпеки, виробничої санітарії, протиепідемічного режиму і особистої гігієни при роботі в лабораторіях (відділеннях, відділах) санітарноепідеміологічних установ системи Міністерства охорони здоров`я СРСР (НАОП 9.1.50-1.09-81)

SAMPLES IDENTIFICATION PLAN

	1	2	3	4	5	6	7	8	9	10	11	12
A												
B												
C												
D												
E												
F												
G												
H												

LOT _____ DATE _____

	Manufacturer
	<i>In vitro</i> diagnostic medical device
	Catalogue number
 YYYY-MM	Use-by date
	Batch code
	Temperature limit
	Contains sufficient for <n> tests
	Caution
	Consult instructions for use
	Conformity Marking with technical regulations in Ukraine
	Authorized representative in the European Community/European Union
	CE Conformity Marking

**For any issues related to operation of the kit and technical support,
please contact by telefon number**

+38 044 294-69-78

or write to:

qa@xema.com.ua



XEMA LLC
Akademika Yefremova St. 23
03179, Kyiv, Ukraine
tel.:+38 050 422-62-16
tel.:+38 044 294-69-78
E-mail: qa@xema.com.ua
www.xema.in.ua